var title_f11_1_11280="Int classification VUR";
var content_f11_1_11280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    International classification of vesicoureteral reflux (VUR)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 215px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADXAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKw/GniG38LeHbrVLobvLG2KPODJIfur+f6ZpNqKuyoQc5KMd2U/HPjbS/B9msl+xlu5ATDaxkb39/Zfc/rXgPif4qeJdakcRXh021PSG0O0493+8fwx9K4zX9avdb1a4v9RmM11O2WY9AOygdgOgFVooy/WvJq4mVR6aI+uwmWUsPG81zS/rYfdXtxcyF7iaadz/ABSuWP60trqN3aMGtri4gYdDFIyfyNXdN0m61O7W10+3e4uWVmWOMZYgDJx+Aqle2U9sxWaGWJumJEKn9axt1O/mXwnb+GPiv4m0aVBNeHUrYH5obv5jj2f7w/X6V9AeBvGmmeMLEy2DGO5jA861kPzx+/uPcV8dnKnitXw3rl7oerQahpsxiuoTkHsw7qw7g+lb0sROm9dUefi8tpYiLcFyy/rc+1qK5/wR4ntPFmgw6jaYV/uTwk5MUg6qf5g9wa6CvVjJSV0fJThKnJwkrNBRRRTJCiiigArD8S+K9F8NRB9Yv4oGIysX3pH+ijn8a4v4u/EgeGEOl6OUfWJFy7kZW2U9CR3Y9h+J7Z+cLy8udQu5bm7mknuJDl5ZGLMx9zXHXxSg+WOrPYwOUyrx9pVdo/iz37UfjrpcUhXT9IvLhR0aV1iz+HJqnF8eYS373w/KF9VugT+qivCArEgDJY8ADuaa5KkqwKsDgg9q5frVV9T2FlWEWnL+LPp3RPjJ4Y1B1ju2udOkbvcJlP8AvpScfjivRLW4hu7eOe1ljmhkG5JI2DKw9QRXw15xVvaux+HvjvUfCV+rWztNp7tmezZvlYdyv91vf861p4ySdqmxx4nJYON6D17M+uaKzvD+s2Wv6Tb6jpkwltphkHoVPdWHYj0rRr0E01dHzkouLcXuFFFFMQUUUUAFRXNxDaW8k91KkMEalnkkYKqgdyTUjMEUsxCqBkknAAr5e+LnxAm8Uak9lYSMuiW74jUHHnsP429R6D8etY1qypK73OzBYKWLnyrRLdne+Lfjba2sr2/hm0F4ynH2q4ysf/AV6t9TivOb/wCK/i+7ckar5C/3YIUUD8wT+tclpum3Woic20ZkMMZlcD0/xrd8IaBaa7DeQySPDeJh4nHIx3yO/Ned7StVla+/yPpPq2DwkG3G9rX6vUt2vxP8X27Bl1uZ8dpYo2H6rXY+G/jhfwyJH4gsIbqHoZrb93IPfaTg/pXnmoeD9as3ZTZNMg6PCdwP9a568t7iymMdzFJDJjO11INJTrU3q38y3QweIWii/Tf8D7N8OeINM8Sact7pF0k8PRgOGQ+jL1BrWr408H+J9Q8M6xHf6ZLtccSRE/JMndWH9e1fWfhLxDZ+J9Dt9T09v3cgw8ZPzRuOqn3H/wBeu+hX9ro9z57MMveFfNHWL/rU2KKKK6TzQooooAKKKKACsTxP4p0fwxbCbWb2ODd9yMfNI/8AuqOT/KsL4p+OofBulKIAk2q3IIt4m6KO7t7D07n8a+Xr6/v9b1Ga9vppru6kO55Gyx/+sPYcCuSviVT92OrPWwGWPEr2lR2j+Z7Xq/x2jDsuj6M7oDxJdS7c/wDAVB/nWQPjrrYbLaVppX0DOD+ea8ojhZ+gruNN8BLd6Sk89y8dxIm9EA+UZ6ZrlhVr1X7rPWrYbAYSK9pHf1Z3mjfHW0kdU1jSJoFPWS2kEgH/AAEgH+deqeH9f0vxDZfatHvIrmHo204ZD6Mp5B+tfHWpaZeabKwubeWMBtuWU4J9j3qfw14hv/D+qx3+k3BhuE4I/hkX+6w7irhipwdp6mVfKKFaPNQdn96PtKiud8CeKrTxdoMd/a4SUfJPATkxP3H07g9xXRV6MZKSuj5ucJU5OElZoKKKKZAUUUUAFFFYvi7xJYeFtGl1HUnOxfljjX70r9lX3/lSbSV2VCEpyUYq7ZrTzRW8LyzyJFEgyzuwVVHqSelcJrPxb8JaZI0a3sl644ItIy4/76OFP4GvDPE3ibxF8QNQcFZXtkOUtIeIoh2yehPufwxXOanoWq2Cb7u0kjj/AL/BA/EVwzxU3rTWnc96hlNGLUcRP3uyaPfV+Ofh0vg2GqBf72xP/i63NH+LHhLU5FjN+9nITgC7jMY/765X9a+UGjkHrU9laX925W0tppyOuxCcfWs44qrfudU8pwtuq+f+Z9wwyxzxJLBIkkTjKujAhh6gin18leDfGeueBdQVCk32RjmWxnyFcdyufun3H45r6i8Oa3ZeItHt9T0yXzLeYd/vIe6sOxBrso11U02Z4eMwMsNaSd4vZmnRRRW5whRRRQAV4H+0pqztqGlaSrfuoomunA7sxKr+QDfnXvlfMf7RIYePWznBs4tv5tXLi3amerk0VLEpvomeXwjc+a774Wro3/CXWMevwvLFI6pCARsEpPy7x3Gf168Vwlp1Fdj8PLF9R8caLboCf9KSRsdlQ7ifyWvOp/Ej6bE/wpXdtGfTlh4Y0jSL671HSdMtob+ZCCyDaD3wB0UE4zgV84/EAeLtSuXv/FFneRRRNsQNGVhiyfur27depr6S8T+ItO8Naa15qk2xOiRry8h9FHc14P43+Jl34osbjTv7PtoNPkIKh8vKCDkHPAB/Cu7FciXLe3kfP5V7Zz9py3W1309Dyq4jxVTJVq1blcA1lzDB4rz0fSnovwa8Uv4e8WW6yyYsL4i3uFJ4BJ+R/wACfyJr6qr4UtHOSAcHsR2r7M8Bax/b3g/StRY5klgAk/31+Vv1BruwU94M+fzygk41l10f6G/RRRXefPhWT4r1mPw/4c1DVJhuFtEXVf7zdFX8SQK1q8v/AGh7lofAsMKkj7ReRo3uAGb+YFZ1ZckHI6MLSVatGm9mz5u1a/uNRv57q7kMtzO5kkc92Jq3oWnSalfwWsTIpduS7YGO/wBfpWOvNwc1pwlowroSrKcgjsa8ZWvqfbzT5bQ0fQ9Qsvh5a22qQ3QupXgjcSCJgM5HI59K5j4hxpda5MlppzRyR8ySqpzLx1wOMe9er2E5OlW0s5w7RKzZ7HGTXLa94v0jybi0VpZWdGjLwrkDIx1OM16dWlTULLS58thcXiJVuZpzaVvT7v1PFZVwSKjVijZFXbhQTx2qnIMV5p9Tc9K+Dvjd/DGuLBdSH+ybxgk6k8Rt0Eg+nQ+30FfUwIIBBBB6GvhO2fDYPQ19afBnXW1zwLZmZ99zZk2spJ5O3G0/ipWu3B1Hd02eDnWGVliI+j/Q7miiiu8+eCiiigDz345a4+jeBZ4oHKz37i1Ug8hSCXP/AHyCPxr5WVszewr6F/aXRzo+iOM+WLiQH6lOP5GvnePic5rysW26jXY+uyeCjhlJdW/8j2T4caGtjZPdySo8t0o4RgwRRyBn15rd07wvZ6frD39tvRnBHlg/KM9cCvHdC1e80e/ils5GwzANEfuuM9CK99iYmIMeOK68M4TiklsePmUK1Cq5OV1P9Olirq0kkFhPJbxmWZELIg/iOOBXi2taTq08F1qupRNGoILNKdpJJwAor0/xD4usNIl8mQPNP1McePl+p7VxfjfxLZ63oEcds0kUyzqzQuOSMHnI4qcS4S0b1XQ0yyNek04w0k1rboedlijZFej/AAb8Yt4b8RxQ3EmNMv2WKcE8I3RZPwJwfY+1ecSjvRbvzjsa4IycWpLofRVKca0HTnsz7uormPhprJ17wRpV67bpvKEUp770+U5+uM/jXT17UZKSTR8NUg6c3B7rQKKKKZAUyaRIYnklYLGilmY9AB1NPrnviJLJD4E1+SIkOLKXBH+6RSk7JsunHnmo9z5W8eeIZvEviS91KUnbM+2FT/BEOFH5c/UmvQPhvosmmaQ01zHsuLkhsEcqvYH+deSwzm11G2mVVYxOHCt0ODXsXhnxZFqs6280P2edhlPmyG9vrXm4Rxc+aT1Pps2hUjQVOlH3Fv8AIq6z4Qln1Jp7JoY4ZTlwRgqe5ArsoIVigRB0RQo/CpgMigjIxXoRpxg211PnauIqVYxjN6R2MnXYrafSbqK82eSY2zu7cda+epgY3yK9t1vwrbXLz3FzfXSx4Lsu4FR379q8avkAdtpyuTgnuK4cW22ro97JlBRkoyvt02Ow+FPjF/CniOOeRidPuMRXaf7OeH+q9fpkV9axuskaujBkYBlYHIIPevhC2fa+DX1b8DNfOs+CIbeZ91zpzfZmyeSnVD+XH/AaeDqWfs2TnWGTiq8d9n+h6JRRRXoHzgUUUUAFfKnxi8VS+JvFk0Vu5axtHNtbKDwxzhn/ABP6AV9L+Kbt7Hwzq13ESJIbSWRSOxCEivjGB9moWrPyEdWOe+CDXDjJbQPeySivfrPdaI918O6VDpOl29pCoBVQXbHLN3JrQubVJYmSVQ6MCCCOCKktiGww6EZq6yZUV2pJKyPDlOUpOUt2eRHwTctrrQBCun7twmz/AA+g9+1ejadpsFjapBaxLHEo4AFaYhAOcUSsFXis6dGNO7R0YjGVcQkpvb+r+pzXinRYNX0uWCRB5oBaJ8cq3auP+CnjU+GfEP2K+k26XeuI5QTxFJ0V/wCh9ue1dzrmq2ul2clxeSqigEgE8t7AdzXzyJi9xI7DG9ixH1Nc2KfJKMo7nqZTTdalOlU+F/n5fgfeVFcL8GfER8Q+B7Rp333dn/osxJ5O0fKx+qkfjmiuyElOKkjxa1J0punLdHdUUVFd3EVpbS3Fy4jhiUu7HsBVGZLXhX7SGhzTXmkapbQvKJEa0cIpY7gdy9PXLflXs5N1dNKEZYLOSEeVKmfODnvtYYGBjrnnqKkhsYY547ht0lykQh85zlivXntknk8VnVpqpHlOnCYl4aqqiV7HyX4f+HXivVJUEGjXMUbH/W3I8lAPX5ufyBr6E+G3w9tPCEbXM0gutVlXa8wGFQd1Qenv1PtXdUVnSw0KbvuzoxWZ1cTHk2XkfM3xivrm68f6hDdMdlsEihXsqbQ3H1JJrh5OBmvp7xp8O9I8V3qXty89tehQjSwEfOo6bgQc49azLL4feFPCMEmr6k0lwtqPM827IZUI6EKBgnPTrXNPDTc2+h6dDNKMKMYJO6VreZ8zXMnUHrVCXkV1Hj250rUfEt9e6ELsWtxI0pFwADvY5OMfw56Z5rl5RxXK1Z2PZhLmim1YbbtiQV9Lfs46gZ/C2oWLHJtbrcvsrqD/ADDV8yREiUV73+zRMRqOuw5+VooXx7gsP61rhnaqjizSPNhJeVvzPeqKKK9Y+PCvMf2hbRp/AiTICfs13G7ewIZf5sK9B1TVbLS4g99Osefur1ZvoBya4vxTrSeItFvNKj06U211GYzLKwUr6MAM8g4PPpWdWPPBxN8LVVGtGo+jPlPBW4Ndf4Q8P3Gt3SbVK2qMDJIRxj0Hqa7qx+GWlxyLJdefOR2Z8D8hiuzs7GCxt1htYkijUYCqMAVx0sG73me3is5i4uNBa92ef/E3UpYBbabbsUjZN8mO46AfSvOWzmvXfGnhaTWZYri2kVJ4wVw/Rh1/CuZt/h9fSSZuriGGPvsyx/DpSr0qk6jaRWAxmGo4dJys+p57ccGqkgyK6bxro6aRqvlW7q9uVG07wWBxzuHY5rnZF+XNc0ouLsz1qNSNWCnHZlRSVavcv2bdWMWs6npjthLmAToP9pDg/o36V4a3DV6F8Frw2nxD0VgeJXeE/RkI/ninSly1IszxlP2mHnHyv92p9ZUUUV7J8SFFBIAJJwB3rlNU8XxiRoNHhF3IODMxxED7Hq34ce9AEfxW8Ov4l8F3lrbruvIcXEC+rr/D+IJH418qWWgalqVwBZWkj84LMNqj6k19KzSatqIJvr6UIf8AlnD+7X9OT+JpkVhDAuEUCuerho1JczZ6WEzKeFpunFX/AEPOPCfgRbOSK71R1mnQhkjUfIp9fc11Xie9fTdCu7iEfPFGSv17VuMAOlU721juoHimUNG4Ksp6EGtI01CPLDQ5amJnWqKdbU+fZZHldpJGLOxyzE8k+tPk066fTHv1hJtEbY0me9epJ4A0pbguTcNH18svx+fX9a2rzSLNtIk07y1jtWQptUY2j1H864o4OWvMz3Kuc01ZU16+n+Z8+Sjgiq6nElbXiTTG0nUXtTPFOAMq8Zzke/ofasNjh65bNOzPZjNTSlHZn0d+zVqRl0fV9Ndv9RMk6D2cYP6p+tez185/s1zlPFeoQ54lsi2PdXX/ABNfRlenhXekj5TNocuKlbrZ/gFFFFdB5oVT1iyXUtJvbGTAS5heEn03KR/Wn6hf2unW5nvp44Ih/E5xn2HqfauO1Dxdd3jGPRIPJi6faJ1+Y/7qf4/lQ1cabTuj5W1O1ls7uWC4UpPA5jkU9mU4P8q7n4d6XPfX9vdmNlt4Du3EY3HsBXpkfhq3mvpr27iSa7mffJK6DLN69K2orJIEAUAY7CuKng+WV2z28TnLq03CEbX6lUrsTJrHv9b0+wk2Xd1FG/8AdJ5/Kti73EEV4xq+kakdauIzbTSySSFgwUkMCeDmt69SVNJxVzgwOGp4iTVSVkjvr/xDo1xZTI97E6OhUquckEeleL38YBO3p2r0/wANeDDE4uNV2sR92Ecgf7x7/SqfxM0RI7OG8s7ZUCErMY1xx2J/xrlrQqVIc8lax6mCrYfD1nRptvm69Lnk5+WSvY/2dNWNr4unsGb93fW5wP8AbT5h+havHpxh6674X3psfHGgzhsD7WkbH2f5T/6FXNTlyzTPXxNP2tCcPI+xKKKK9k+HCiiigCnrNn/aOj31kcf6RA8P/fSkf1r4vtrCebWoLLYftBl8plx0IOD+WDX2Zq2sWWlR7ryYBj92NeXb6CvJU0Syl8UahrVvbNFJduXCMQdmfvY9MnJP1rmr0PaSi+x6eAxywsJxfXb1NSyi2xoo7ACtIJ8tMt4CMcVbKcV0nmFKXgGs+ZiTWlcKcGuI8Y6jq+nmL+yrQTIwO9thcqe3AqZSUVdmlKm6s1Bde5yPxQ0WC0SC+ikkLyuUdJJC/bORnp9K8zkG18iuq1+41bU5fN1FLhmXhVMRVV+gxXMXAxXlVJKUm0rH2GDpyp0VCcrtHs37Nmsm28S3emOx8u9g3qP9tOf/AEEt+VFcL8LL86d440O43bVF0kbH/Zf5T+jUV14SfuNPoeJnNF+3U4rdH2TWfZh7yeO+Y3luoV4hbS4VT833yOuTjjJ6HpzSamEu54dPdbsLIPOaWElVARlO1m/2j2HUA1o12HjBRWfb3D6i1vc2NxH/AGeyuG/dne5zgbScYHBOcHPGOK5L4lTQeF/AdxdQtLJexHZaT3EjSyJLIcbgzEkEAkj6VMpKKcmXSpurNQju9DvaK+RdK+IvizTrpXh1u7mUdY7lvOU+x3c/kRX0D8MPH8HjO0limiW21S3AMsKnKsvTevtnt2rGliY1HbZndissq4aPO9V5Hc1zXxE0GbxJ4SvdOtJAlw2148nAZlOQp9jisb4yeJL7w74cgOmOYbi6m8rzgMmNdpJx7nH868OXx94ot1lUa1dSpIhRlmIcYIxxnofcVNavCL5JIvBZfVqxVeDSs9PkcpdwvBcywTALLGxRwCDgg4PI61nXAxmrJ+Wqs7V5p9SivH/rRXuv7NKn+2dbbsLaMf8Ajx/wrwyAZlFfQ/7NNoVs9dvCOHkihU/7oJP/AKEK1w6vVRyZm+XCT+X5o9rrA8Ta9/ZoW1tAsl/KMqD0jX+839B3rX1C7jsLGe6nOI4ULt+HavPdNElzLLf3vNxO29vb0A9gOK9c+NJLawMkrXV9I8078tI5yT/gPYVYkuYIhtULVPUb9y6xQqzyOdqogyWPoK1NP8IXM6iTUrryCefKgAJH1Y8fkKAMxroMacH3c15h458YtpHii7sdEPm2do3lM853F5B97BGMAHj8K0PCXjy31OdLa8j+zXD8LzlWPoD61jHEU5S5b6nbPLsRCmqrjpud+enWqGoI8ttKkTbXZSFYdjjrRrF2LPS57oKWESF8DqcCvNl+IN4s2XtITF/dDEH86dSrCnpJkYfCVcQnKmr2OK1mwubK6dLuGRJATksD83vnvWbL92un8beIn1y6iEQeO0jUFYz1Ldyf5Vy0x4ryqiipWjsfX4eU5U06isynJ1rsPhgSPHPh4j/n9iH61x79a7b4Twmfx94fRRki6V/++QT/AEpR+JepdbSlN+T/ACPr6iisPxlqb6ZokjQNi5mYQxH0Y9/wGTXtnwZz/ijV31W7k02zciziO2Z1P+tbuufQd/U1DawRW0Q4AxVbSrZbe2UAdBVfVL4RoxLYUUAXZ79V4WqT34Y43D86teGvC8+sot7qjyQWTcxwodrSD1J7D9T7V578a9dstO1GPQPDsMVsbbD3U8f3y5HCbuuADk89SPSs6tRU48zOnC4aeKqezgdykwY81LkYrxjwp4yv7W9ii1Gdri0dgrF/vJnuDXsEkgjtWkY/KqlifYUqVWNVXQ8Vg6mFkoz6krYry/4oXOo/bFhPmR6fsBBXO1275P8ASo7rx7qD3LNaxQpbg/Krgkke5zW3H4vt7jw9cXc0KG4hwrW7NwxPAx7VjOrTqpxUrHbRwlfCTjVlDm6feePzrxgVRb71amoyiaeWURpHvYtsQYVcnoPas1+WFecj6f1PX/2cgf8AhN5f+vGT/wBCSvpWvnb9mq3LeJtSnxxFZBc+7OP/AIk19E16WD/hny2cu+JfogrB8VeIY9EgRI0E9/N/qYc/+PN6KP1rQ1rUodJ02a8uMlYxwo6ux4Cj3Jrzq1jnvryS9vTvupjlj2UdlHsK6jyhI7W51O7F1qcrXFwemfup7KOwrfgskiUZxToVWBBgDNV7m+C8A0AW22L0AqtKd1Zz3/PJpUvA3cUASTJzyKrNCmc4qd5MjNULi+giYLLMiE9AzYoAi1O+g062aa5YJEvGetczfeNtEEEiySPICpBTyid3tXQ6lbQalatBcKHib3/UV4/450eHRruNILoS+Zk+WfvJ9fauevOdNXjax6WX4ehiJclRvm6WOQvmVpnZF2oWJVfQZ4FaXhtzHqmnyDqtzEw/BxWVcnmtvwhAbnXtKgUZMl3Cv5uK8tn1miTPteiiivcPgQrjPEPimRpXtNGYcfK911APonr9ab431pzP/ZNo5XgG5dTyAeiD69T7Vi2NsDgYwOwoAitrNpZDJIzSSscs7nLH6mti3swoHFTRRrGo6U/eM8mgAEaqOKZIM09nB6VEze9AFaZeuaz5YgSavzPmqslAFKSPb71418XrS2t9Yt5LdVSWaItKFGMkHg/59K9c1i4ltrC4mgiMskaFlQfxH0r598RahcanfSXV4+6V+MYwFHoBXJi5pR5T2MmoylVdRPREehymG+tpQcGOVHH4MDRRo0ZlvbaJRkySIn5kCivPjzdD6GsqenOfbNhLHPqGotFeNMI3WFocYELBQxA9SQwP5U7V3K2TRx3iWc0zCKKVgGwxPGAep9KfZfaPOvPtEUMaed+6MZ5dNq8t75yPoBSXiytcWapbxSxeaTK0h5jAU4ZR65wPxNe2fDFuvIv2kZJF8L6XGpPlPeZb6hGx/WvXa4D446S+qfD+7eJd0lk63QAHOF4b/wAdJP4VjiE3TkkdmXzUMTBvufKsZ/fHNes/s9adeT+Mpb+FWWytoHSZ/wCElsbV+vf8K8jm+WTIr2f4bfFe30Twtf2epWtsstoitZR28fl+ex4IbHGc4Jb0z1rzaHLzpyZ9RmCqOi401dvT7z2/xRoVp4j0W402/B8qUZVx96Nh0Ye4r5l8Y+DdU8MXTx30DyW+f3dzGpMbj69j7GvZPhf8RLzxauqx39rawTWkYlR42KoQcjDZJxyOtc1qHxbnuPB+t2l2I9N8SQDyowmSr5YK23OcMBn+YrrrezqJSuePglisNN0krq6ur9+v+Z4fc4ArOnbiprifcTzk1VwXbFcB9GT2S87jX1t8F9IbSPh/YCVSs13m7cEc/P8Ad/8AHQtfOvw58MyeJvE1npyqfs+fMuXH8MQ+9+fQe5r7BjRYo0jjUKigKqjoAO1dmDhduZ4ed10oxorfd/oc18QZiNJt7YHH2m4RGHqoyx/9BFYM8ggtQq9SK1fiDzNo4PTznP8A47XO65L5Vs7D+FCf0r0D5w3vAVgJpJtUmXOGMUGewH3m/Pj8DXT65ejTdFv749LaCSb/AL5Un+lM0C0FjoljbgYKRLu/3sZP65qLxZatfeF9XtUBLzWksagepQgUpbOxdNJySex8XXsryMZJCS7ksxPcnkmpYchAwJBHII7VVuydqGuj8DTaWNUhGrIzKSNhJ+RW7bhXhwjzNK593Wn7OLla9uiPadBZ7zw7afblzJJCvmBh1yOc1574p8EXNm0lxpame26mIcun09R+tdnYeKdMutS+wQSnzOVU7flYjsD3rPuPFosPEFzYamiwwDmKUdxjPP15r1aipziuZ/M+Tw0sTQqN0420vbyPHpxhiGBBBwQRgiqUhyTWz4l1R9Y1Sa7ZFQMcKoGML2z71hTHaDzzXmSsnZH1VNtxTkrMiPLivW/2e9NN347S5IyllbvKT7t8g/8AQj+VeTWyFnya+n/2fNAOneFZtUmTE2oyZTI/5ZJkL+ZLH8q0oR5qi8jlzKsqWGl3en3/APAPVK4Xx3L5+uafa5+WGMzEe7HA/kfzruq8519vM8Z3wP8ABHEo/wC+c/1r1z40JZNkBxVDQ9O/tzxBHBKu60gHnTeh9F/E/oDVrUjsh49K2fhhB/xKLu8YfPcXDAH/AGV4H67qAOp1K5Ww0y6uiBtt4Xlx7KpP9K+JtRu5r69murly887mWRj3Zjk/zr7V1y2a90XULVPvT28kQ+rKR/WviSdChwwII4I9DXn4694n0eQpcs310/U2/D2h3es3UUdvGwh3DzJSPlUd/wAfaveo4l+zCIjK7duD3FeRfDXXzZXiafOc287fKf7r/wCBr1aG8imnkijlRpE+8oYEr9RWuEUVC63OPOJ1ZVuWa0Wx51rfga8huHfTdstuxyqFsMvtzwa5nWNF1LTbUzXVqY4gcbiwPX8a9Z1TxHZ6bqUNldlleUAh8fKMnAya8v8AiNqkt5r00DN+4tjsRAeM45P1rGvSpRTa3O3L8Viqsowna1r3a3RyFw2agiXdIKWZ8mrOm28k80ccKF5ZGCIg6sxOAPzrk2R7Z9D/ALN2mGHQdU1Flx9pnWJD/soOf1Y/lXsNYngrRF8O+FtO0tcF4Ih5hH8Tnlj+ZNbdevRhyQUT4nGVvb15VFs2cF4/u/tGsWWng/u4V+0SD1Y5C5+gB/Oo7BQq59qztZfzvGGrOf4XSMfQIK0YGwmBWpzC3k+xTzWG73F3eR2tlEZrqX7qDgAdyT2A9as6nNt3sx4UZrqfh/pgt9LF/Mv+lXg35PVY/wCEf1/GgDzL4s2U/hXw9YS/bnfU7qcqdgxGqBSSAOp5K8mvMtG8YavBcb3uTNGp5RwOR9a9J/aXldtS0ODJ2CGVx9Syj+leafDbS4NV1uWO75jhTzPL/v8AOMfSvOqznKtyxZ9LhaNCnglVqxT3b013Pb7G4+1WMM2CPMQNg+4rzXxlpeoPrFxP5EksLEbGQbsDHT2r0uIqiBRwAOBTjtPWuyrSVSPKzxMLinhqnPFXPNNL8Ralp+mPBPZTSlFIjkZSNvpnjnFef6lO89w8krl5HOWY9Sa+hpvLSNnYgKBkk9hXgPiW6t7jV7ye0QJA8hKAenr+PWuPEwcEk5XPbyuvGrUm4w5e7MOXlsV33wZ043/xA0ZMZWGQ3DewQEj9cVwSAvIK+gv2b9BKpqOuSrgNi0gJHXGGc/ntH4GsKUeeokehjaqo4ecvK33nuFR3Uy21tLPJ9yNC7fQDNSVi+M3MfhbUmXr5RX8zj+tewfFHntoz3c0lzNzLcOZH/HtW/aIETNY+mjCJ9K1i22OgAmuNtVjd89ap3UpLHmsi91SCzUtczJEvq5xQNJvRHTJcZpTJkVzulaxaagpezuI5gODsYHFbCvkZoTvsDTTsxZ5duc1QXUIHkZFkUsvUA8irNwu9CK8x1rwjqFrdSXmkzO77i+3dhx9D3rOpKUVdK5vh6VOq3Gc+Xt/XQ9HkZXHqK8A8fLFH4p1COAAJ5gOB6kAn9a3JvGutW8LwM0SyL8pZovmB+nTP4VxFxI9zdPJK7PI7bmZjkknvXFXrxqJJHvZbgKmGm5za1VtDqfhnp51DxrodvtyGu42b/dU7j+imivQP2cNENz4jutWkX91Yw+Wh/wCmj8fooP50VrhILk5n1OPOK79soReyPebSGO31u/MdvOHuEjmeZjmNiAU2r6EBQT9adqAjGo6Yzw3EknmOqNHnYmY2yX9sDA9yKqeIL6PSrizv7ia58n5oPJjAKOzYILZ7jacfU1nXXiSGe70yNDdW4a5QErtw4IKhW9skH8BXYeKdZTJoknhkimQPHIpVlPQg8EU+igD4++I/hOfwt4huLB1Y2rEyWsp6PGenPqOh/wDr1xu9ojhga+1/F3hjTfFelGx1WLcAd0cqcPE395T/AJBr598WfB/xBpUjvYQjVrMfdeAYkA90Pf6Zry62HlB3iro+swWZ060FGq7S/M8zj1GZLaW3SZ1glIMkYbCuRnGR3xk1WeckVoX2kXFnIY7y1ntnHVZo2Qj8xVVbZM43A/jXNc9RRvqiqoZzWhp9lLcTxQW8TyzysESNBlmY9ABXQeGvBWua9Kq6XplxIhPMzqUjH1Y8flmvoX4afDSy8JAXt26XmsMuPNx8kIPUID+rHk+1bU6Mqr00RxYrHUsLHV3l2LXwp8FJ4Q0L/SQrardYe5cc7fSMH0H6nPtXcUUV6sIKC5UfIVasq03Unuzk/iDGfJ0ubslztP4o3+Fcprw3RY7NtX8yK7jx1AZvDVy6jLwFZh/wFgT+ma4XWTv03zBzhQ35c1RmesgYGB0opsTiSNHU5VgCKdQB8i/FLw43h7xdqFlsK20jG4tjjgxsc4/A5H4VwodoXwa+v/il4Jj8Y6MogKRapbZa2kboc9Ub2P6HmvljW9HutOvpbLUraS2u4zho5Bg/X3HuOK8ivS9lLyZ9ll+MWJpJX95b/wCZWstTltpo5oZCksbBlYdjUl5qs95J5t3PJNJ/edsmsySxkz8ppi2kvesr6Wudjgr81tSxNdDBqqheZ/ap47Ek/Oa6Dwz4dvtd1OPT9ItjNcP1PRUH95j2FHkhu0VzS0SL/wAO/Ck/irxDb6fEGWAYkuZQP9XGOv4noPc19fWlvFaWsNtbII4IUEaIvRVAwBXO/D/whZ+D9EW0tyJbmTD3NxjBkf8AoB0A/wAa6evUw9H2cdd2fJZljfrVS0fhW3+YV5rroK+N9Rz0ZImH/fOP6V6VXnnjJPJ8Ywydp7UfmrH/ABFdB5pT1o4ts+1db8PFA8Hadjurk/i7VymrpvtRjuMV0fw0m3+F0hP3reaSI/8AfW4fowoA6qvk/wCMPht9A8Y3qKhW0vGNzbsBxhjll/Bs/hivrCue8beFLDxdozWN+Cjqd8M6j5on9R6j1HesMRR9rGy3R6GXYz6rVvL4XufGUczwSAglSDkEdq9F+Fl2i3GqXl1MqoiLvkkbHUk8k/Ss3xn8Ptb8NSv9us2mtAflu4FLRke/dT7H9a4xrZ9pEUh2HqAeDXmwk6U7yWx9PWpxxlFxhLR9fmelePtX0HWLMyWuoIb23B2AK2JB/dzivM5py7EsST70C1l7mpI7TLAHJJ4AHU0qlX2j5mVhsL9Xh7OLbXmQRIZG9q9z+AXghri7TxJqMWLWAkWasP8AWSdC/wBB0Hv9KofDX4S3mrSxX3iGGSy0xcMIGG2Wf2x1Vfc8nt619F20EVtbxwW8aRQxqEREGAoHQAV04ag2+eWx5WZ5jGMXRpO7e7/Qkooor0T5s8q1ZfK8X6wh6mVXH0KLWpbDKg1H49tTa+JLW9Ufu7uLymP+2vI/MH9KLGTK4oAzvEEDG3mC9Spr0bw/cR3WiWMsONjQrj2wMEfpXG6lHvhzS+ANRaz1SbSJj+5mBmtz6MPvL+XP4GgDA/aN0Z7nRNO1aFCws5GilwOiPjB+m4AfjXz1Z3MmmapDdxFgY3DcHGcHpX25qNlb6lYXFlexLNbToY5EbowNfLfxH+HWo+FbmSVY5LrR2P7u6UZ2D+7J6H36H9K87FUnGXtIn0mUYuE6f1ae/TzTNebxvHf6vpNtpDsI5ZV88suDg/w//XrstWt5Lywkigne3lI+WRDyDXz/AGTy2N7BdQYLwuJFB6HBzXa3/wARr+QxfYbOKDacv5h37vbtiqpYqLT9ozPFZVOMoLDrRdX38y/qvjG5sLK70zVLTdfBDHvDYUgjG7H+FeYSEucCtPWtQu9a1F7y8KiRgAFUYCgdAKl0PQ77Wb+Ox0q2kubp+ioOg9WPQD3NctSo5u2/Y9bDYaOHhzNKLer7B4W0O713WLXTdPTdc3DYBxwg7sfYDmvsXw5o9toGiWemWQxBbRhAT1Y92PuTk/jXM/DDwFbeDdOZ5Sk+rXCjz5wOFH9xf9kfqfwA7iu/DUfZrmluz57NMcsTJQh8K/F9wrK8V27XXhvUok5YwMR9QM/0rVPA5rlNV8b6ZbSvBbRy3zjhjEBs+m49fwzXUeUcnp0gNvEw6FRWmx3R5rmNIvEfzo1QxqkjBUJyVGeBn6V0Nq+9cZoAz7sH5q4n4m6IW8F6Zq8a7mF5LFO3oGxs/D5f/Hq9Du4M5wKdo9taapZaj4a1Qf6LfqWiPdX749xgMPpWdaHtIOJ04Ov9XrRqPofNOiancaLqaXFuxDA4Zc8Ovoa990DU4tT06G6gbKSLkeo9Qa8Z8beEtQ8M6s9lqUZHJMM4HyTL/eU/zHUVr/DjxHDpKyWGoyeVEz745G+6CeoPpXDhqvJLkloe9mmFWIpKvS1fl1R67LJtBPas9NRs5gzJcwkKcHDjis7WvEOnWemTTyXkJ+Q7ArgljjgACvBHkkk/HrXVWxHs2ktTy8DlzxSk5O1vI6H4hX1reeJrqSxZWiwql16MwHJ/z6Vh6day3NxHHDG0k0jBERRksxOABSQ2rMRwSxOABySa+i/gr8Nn0gx69r8O2/I/0a2ccwA/xt/tEduw9+nBGLrz0PoKtWGBoLmd7Ky8zu/hx4ZXwp4UtdPbabpv3tyw7yN1/AcAfSiuoor1oxUVZHx9SpKpJzluzC8b2hvPDN4EGZIlE6fVDu/kCK4G8zPoyXEB/eR4kUj1HI/lXrTKHUqwBUjBB7ivK9OgNrLqGly9beVo1z3Xqp/IimQem6fdJfWFvdRHMc0ayL9CM1Yrk/h1dltMuNPkP7yylKqP9hvmX+o/CusoAKKKKAGyRpKu2RFdT2YZFV006yRtyWdsreoiUH+VWqKLDTa2CiiigQUUUUARXUK3NrNBJykqFG+hGK8sgjZ9Je3lH7yBmhcH1Bwf5V6xXnmrwfY/Fd9ARiK7QXCfU8N+oz+NAHUeC7w3nhuzZjmSJfJf6odv8gD+NbdcT4BuDBqOo6e54fFxGP8Ax1v/AGWu2oAKyPEXhvSPEVuIdZsYbpR91mGHT/dYcj8DWvRSaTVmVGUoPmi7M8f1X4GaXM5bS9Vu7UdklQSgfjwf1NYT/AnUd3ya3ZlfVoGB/nXvtFYPC0n0O+Ga4qKtzfgjxjSPgVaRyK+r6xNOo6x28QjB/wCBEk16n4f0DS/D1l9l0ezjtourbRlnPqzHkn61qUVcKMKfwo56+Mr4jSpK6CiiitTmCuK+JVsQmmago/1Exic/7Lj/ABA/Ou1rP8QWA1TRruz/AIpYyEPow5U/mBQBw0n76yGOSKs/Dm4NvrGpWDn5ZlW4jHuPlb/2WsrQrgz2YDja44ZT2I4Ipkc50zXbG+6LFKFk/wBxuD/PP4UAesUUUUABAIweRXPap4K8Nao5e+0Sxkc9XEQRj+K4NdDRScVLdFwqSg7xdjiD8K/Bu7d/Yy/Tz5cf+hVt6L4S0DRHD6XpNnbyDpIIwXH/AAI5P61uUVKpwWqSLlia01aU216sKKKKsxCiiigDnfH1n9q8M3LoMy22LhP+A9f/AB3NcfpkodUYdGFem3UQntpomGVkQoR7EYryfw3k20KnqBt/KgDo5/mtzmud3mDXNJmT7yXaLx3BOD+hroLlgkRHtWNp0X2zxRpUC84m85vogz/PFAHqtNdVdWV1DKwwQRkEU6igDiNb+F3hTVpGlfTvskrHJe0cxZ/4CPl/SuZn+BeisxMOqajGvo2xv/ZRXrtFZSoU5bo64Y/E01aM2eW6f8EvDdu4a7uNQu8H7rSBFP8A3yAf1r0HQ9E0zQrX7NpFlBaQ9xGuC3uT1J+taNFOFKEPhRFXFVq2lSTYUUVneIb7+zdFvLoffRDs/wB48L+pFaHOcj4t1qbUruXTLFylnEdk8inmRu6j2Hf1rJi00JGAqgDHTFSaLbhIlzy3Uk9zWjK4XqaAOP1SzlsboXcSkxkYkA9PWtPTroEKysCp5BrXljSZCMAg1hrpotblmhJEbc7OwPtQB0MbCRao6nbMu2WFikqEMjjqrDoalsSQOatXADwsKANux/s7xn4eMOsWcNxtPlzwuM7XHcdxnqCPWuB134GadO7SaNqc9pnkRTp5qj6HIOPrmuj8ByNF4jvIVP7uW3Dke6sAD+TGvQKznShU+JHTQxdbD/w5WPnSb4E66rfur/S3HqS6n/0E1Y0/4Eao0g+36tYwx9/JjaQ/rtr6DorH6pS7HW84xTVrr7jifBnw10HwvIlzDE95qC9Lm5wSp/2R0X69feu2oorojCMFaKPPq1p1pc1R3YUUUVRmFcD4yg+w+J7W8AxHeR+W3++v+II/Ku+rmviFbiXw3JOPv2siTj8Dg/oTQBg6BN/Z/jGIdIr6MxN/vD5l/kR+Neh15VqMxjtrK/T71vKkv5EE/pmvVQQQCOQeaACiiigAooooAKKKKACiiigArkfiFblLey1NB81rLskI/uPgf+hba66qmr2S6jpd3Zv0mjZM+hI4P50AefR3H2HxFpd8DiNnETn/AGX+X+eD+FemV4+d934fAfImjBU+oYf/AFxXq2lXP2zTLS5/57RK/wCYzQBaooooAKKKKACiiigAooooAKKKKAPMtZt/7L8V3kSjEVxi5T/gX3v/AB4H86q6xEJrd1/vKRXS/Ea1xDYaio+aCXynP+w/H8wPzrDkHmWefSgDufCt6dQ8O2Fwxy5iCv8A7y/Kf1BrVrj/AIZzZ0y9tT1guWIHswB/nmuwoAKKKKACiiigAooooAKKKKAK2pTi1066uG6RRM5/AE15f4YQpZwl/vbQT9a7X4hXPkeF7hAcNcMsA/4Eef0zXLabHshGOgFAEmoS/Kea1Ph9pmXuNYmHzS5hgHogPJ/Ej9K5nW5W8lwh+dvlX6mvUtMtVsdOtrVPuwxqn5CgCzRRRQAUUUUAFFFFABXK/EiTboUCdpLqNT+p/pXVVzvj6ye88NzGIFpLdluAB32nn9M0AcvpzgLTb8tnI6VSspwyKwOQRWmAsyUAY8GpeVdNBPhSeUPZh/jWks0b8nFVr7TEnjKyLuHb1H0rLa0v7M/uG8+P+65ww/HvQB0YmRRxioZ7sBTzXPPqjQnFxbzoR/sZH5it7TfDuqax5bOq2dk4BMpYMzD/AGQP5mgDW+Hds015f6iw/d4FvGfXByx/PFdzVfT7ODT7OK1tU2QxLtUf1PvVigAooooAKKKKACiiigAqhr8IuNC1CEjO+3kX/wAdNX6ivBm0mB7ow/SgDyeI/afDJB6mP+len6FN9o0TT5icl7eNj9dory7Q+dBAP9wD9K9F8Fvv8K6YfSEL+XH9KANqiiigAooooAKKKKACiiigAooooA8xuYfs+s63aYwBOZVHs4Df1Ndd4El8zwxaqTkxM8R/4C5A/TFc94hUL4vvcfx20RP1+Yf0rY+HbZ0i7X+7duP0U/1oA6miiigAooooAKKKKACiiigAooooAzPE9p9t8P6hb4yzQsV/3gMj9QK4LR5Bc6aG7lA1ensAykHoeDXlXhYbYHhP8BdPyJFAGz8P5PK13Urfp5kSS/8AfJI/9mFd7XnPhc+V41iA/wCWlvIp/Aqf6V6NQAUUUUAFFFFABRRRQAUUUUAcb8TCfsOmD+H7WM/98NWXYj/RSa2/iVEX8OpMo/1FxHIfpnb/AOzVh6e2bQigDNkj8/WNOhPR7qMH6bs16zXlVuQniPSmPQXSj8+P616rQAUUUUAFFFFABRRRQAUEAggjIPaiigDy7xFpLaDqR2A/2dcMTE3aNu6H+nt9KhgnK4weK9QvbSC+tZLa7iWWFxhlavPtX8KajprtJpgN9adfLJxKn/xX86AHRXII5qdRHIOQK51LxUlMcoeGYdY5FKsPwNX4bnGOeKAL81mjg4FVLeO80uQyaZO8BJyUHKN9V6f1qaK69TV2KRZB2NAGpoXiqO6lS11NFtbtjhWz+7kPsex9j+tdPXm+p2McsRyoZT1FbfgjV5pXl0y9cySwrvhkbq6dCD6kcfgaAOtooooAKKKKACiiigAqvqLiLT7qQ9EiZvyBqxWR4vm8jwxqTg4JhZB9W+X+tAHnOlDy9AQn+6P5V6J4NiMPhbTFbr5Kt+fP9a89vB5GiCNfvFdq/U8CvVrOEW9pBAvSNFQfgMUAS0UUUAFFFFABRRRQAUUUUAFFFFAHnmsP5njDVj2iiij/AB25/wDZq2fhyhGiXLn/AJaXcrD8ML/SuXW4E8+sX38M1y+0+qqdo/QV23gmAweF7AOMM6GU/wDAyW/rQBuUUUUAFFFFABRRRQAUUUUAFFFFABXlWg/Ld3WOhuJcf99mvVeleT+HTuQyH+Jmf8yTQBf0A/8AFb2Q/wBiX/0GvSa838ML5vjaBh/yzglc/oP616RQAUUUUAFFFFABRRRQAUUUUAUdcsRqWj3lmes0RUex7H88V514fmL2qhxhgMMPQjrXqdeZ6hF/Z3iq/twMJIwnT6Nyf1zQBR1UmCVZ16wuso/4Cc/0r1iN1kjV0OVYBgfUGvMtWiDxn0YEV2vgy6N34ZsHY5dY/Kb6qSv9KANqiiigAooooAKKKKACiiigAooooAq3+n2eoR+Xe20U69t6g4+h7Vzd74HtGJbTrqezb+7nzE/I8/rXXUUAea3+g6tpcTSyol3AvJkgzuA9Sp/pmqtpdZ2sjZU8g16pXk8yImr6jHb48hblwgHQc8gfjmgDdibzI8HvVLTG+yeJ9PkHAaQxH6MCP54qxanZFk1RT99renhev2qMj8Gz/SgD06iiigAooooAKKKKACuW+IM+NNtrRT81xMCR/sr8x/XbXU1wHiS4+2+J5FHMVnGIx/vH5m/9lH4UAUIYPtmu6VZdV80SOP8AZT5v5gV6dXDeBLc3Os3+oMPkhUW8Z9z8zf8AstdzQAUUUUAFFFFABRRRQAUUUUAFZ/iG+/s3RL27zho4iV/3jwv6kVoVx/jyf7RNYaWp++/2iUf7K/dH4t/6DQBy0kDRaRbWUfM05WIe5Ygf1r1a3iWCCOKMYSNQqj2AxXB+H7f+0PFMbYzDYp5h9Nx4Uf8AoR/Cu/oAKKKKACiiigAooooAKKKKACiiigCrqs32bS7yc8eXC7/kpNeZ6DH5WnpnqEH8q7fx3P5Phi8UHDTbYV/4EwB/TNcfF+6sT70AafgKLzNd1C47RwrHn3Zif/ZRXeVyvw8g26ZdXJGDcTnB9VUBR+oNdVQAUUUUAFFFFABRRRQAUUUUAFcH8Q4vK1nSrkcGRHiP4YI/ma7yuH+I5DXejxj7waR/wAA/rQBm3Hz2oNb/AMOGP9j3UR/5Z3T4+hAP9TXPyHbac+lbvw2BbSr2X+F7pse+FUUAddRRRQAUUUUAFFFFABRRRQAUUUEgDJ4A70AFY+q+I9P05zE8pmuB/wAsYRuYfXsPxNc9rniCfUZmtdLdo7QHa0y8NJ/unsPfvVG2sYbdPmAB9KALd/4k1K/Qx2kQsom4LZ3SY9j0H61QsrFYUGeAPWppJUTpgVUuLxVU5YAe5oAnupwq7VNWfBlob3WjdEZhtAefWRhgD8Bn8xWVptje65PssVIhzh7hx8i/T+8fYV6TpOnQaXYR2lqCETqT1Y9yfc0AXKKKKACiiigAooooAraneR6fp9xdy/chQtj19B+J4rzDzXgsZric5nlJkc+pPJrqfHV55slvpqHgkTTfQfdH55P4Vj6LY/2rrcEJGba3xNL6HH3R+J/QGgDsPCentpug2sMoxOw82X/fbk/l0/CteiigAooooAKKKKACiiigAooooACcDJ6V5lPe/bNQ1DVHPyO3lw57RrwPz5P411/jO+NpozxRHFxdHyUx1AP3j+Az+lcfa2X268s9LjH7tiDJjsg+9/h+NAHWeBbE22jfaZVxPeN5zZ6heij8ufxNdFSKoVQqgAAYAHaloAKKKKACiiigAooooAKKKKACiiigDjfiFPufTbIH7ztOw9lGB+rfpXP6kxis1VBlzwo9T2q74gm+2eKrp85S3VYF/Dlv1P6Umkwf2h4ks4sZjhJnf6L0/wDHiKAO60ezGn6Xa2i/8sowpPqe5/PNXKKKACiiigAooooAKKKKACiiigArznxRP9u8VyheUtI1hB/2j8zfzA/Cu51nUI9L0ye7l5Ea/Kvdm6BR9TivNbUtHC81y2Z5CZZW/wBonJoAk1OVvLWCFS8zkIijqzHoK9D8P6cuk6PbWakFo1y5Hdjyx/Mmub8FaSZ5RrF2pwQRbIew7v8Aj29q7SgAooooAKKKKACiiigAooooAK5PxtqbYTS7ZiHlG6dgfup2X8f5fWusJABJ4A5ry23me+vJ7yb78zl/oOw/AYoAtwBLaIBQAarNNPc3KW1nG01xJ91F9PUnsPem304RGPYDoK7jwto66XYh5QDezgNMx6j0UewoAybLwbvUNql5IznrHB8qj8Tyf0rVtvCujW5DCySVh3mJk/QnFbdFACIiogVFCqBgADAFLRRQAUUUUAFFFFABRRRQByt54Zubm/nuXuoy0rZ5U8DsPwFa+gaTHpNo0atvlkbfJJjG49vwArn9c8cnSfHuj+Fjod/cT6oC8F1HJCIti4MjEFww2A5Ixk/w5rs6ACiiigAooooAKKKKACiiigAooooAwtd0STU72KcTqqxIVVCOASeT/L8qfoGhLpc088kvmzygLnGAq9cD8f5Vm/EnxongXQk1a50u8v7TzVikNs0YMZYhVJDsM5JA4z71Sj8fzf8ACeWPhW48NanBfXVmt95jTW5SOLA3k4kJO1yUIGckEjIwaAO5ooooAKKKKACiiigAooooAKKKKACiiigDkf8AhFbgSzP9qjZpHZyxBByTmtXw/oa6U80rSebPKAC2MYA7D865+Tx/N/wnl94Vt/DWpz31rZtfeYs1uEkiwdhGZARucBADjBIJwMmsD/hc8H/CDf8ACWf8IvrH9lfavsmfNt927fszjzM43/L+vTmgD1iiobGWW4srea4t3tZpI1d4JGVmiYjJUlSVJB4yCRxwTU1ABRRRQAUUUUAFFFFABRRRQBz3ijR7vVpbcRSxrbxHd5bZ+Z/U/QfzrPg8IvLMn2+VDbg5aNM5f2J9Kl+JPjRPAuhJq1zpd5f2nmrFIbZowYyxCqSHYZySBxn3rLl+KGnWT+JodasLzTLvQLCLULiCYoxkSRN2IyrFWIbCHnG48EjmgDv1UKoVQAoGAAMAClqppF42oaVZ3r28ts1xCkxglxvj3KDtbHcZwferdABRRRQAUUUUAFFFFABRRRQAy4jMsEkYO0upXPpkVy0HhOSBNqXKEYxytdZXN+LfF1p4X1DQLfULecw6xeiwS5QDZDKwygfnPzYIGPSgCG38JkXcMtxcB0jcOUC/ewc4rqq5/wAK+KLbxLda3HYwTLDpd89g0742TSIBv2c9FJxn1BroKACiiigAooooAKKKKACiiigAooooA4TxD4K1PVfiToPimDXba2h0lXjSyawMhkSTAlBk80YJA4O35fQ13dFFABRRRQAUUUUAFFFFABRRRQAUUUUAcX8V/Bl5478NLo1rq0WlwtMk0rvaG4L7GDKB8645Az1qkvgbW3+JWneLrrxFZyNbWC6fJapphTzEOGkIbzjtJcFhwdoOOcZJRQB6DRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnzeBtbT4laj4utfEVnG1zYNp8dq+mF/LQZaMlvOG4hyGPA3AY4zkcx/wprV/wDhWv8Awhv/AAltr9k+2/a/P/sg7v8AWeZtx5/9/v6cY70UUAew2KXEdlbpezJPdLGqyyxx+Wsj4+ZguTtBOTjJx6mp6KKACiiigAooooAKKKKACiiigDi/iv4MvPHfhpdGtdWi0uFpkmld7Q3BfYwZQPnXHIGetYvjf4UJ4w1/w9q2o6uYp7OGO31SOG22x6nEkiSiMjf8i+YpOMt19s0UUAenUUUUAFFFFABRRRQAUUUUAFFFFABXMfEjwlF428I3eiy3LWcsjJLBdom5reVGDK4GRnBHqOCaKKAJvAHhiLwf4TsdFiuGu3gDNNcuu1p5XYs8hGT1ZicZOBgZOK6GiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: International Reflux Committee. Medical versus surgical treatment of primary vesicoureteral reflux. Pediatrics 1981; 67:392.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11280=[""].join("\n");
var outline_f11_1_11280=null;
var title_f11_1_11281="Celiac disease Endosc";
var content_f11_1_11281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Celiac disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scalloped duodenal folds seen on endoscopy in a patient with celiac disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11281=[""].join("\n");
var outline_f11_1_11281=null;
var title_f11_1_11282="Patient information: Tonsillectomy and adenoidectomy in children (The Basics)";
var content_f11_1_11282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"26\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/42/6818\">",
"         Patient information: Anesthesia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/9/20626\">",
"         Patient information: Ear tubes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/45/25298\">",
"         Patient information: Eustachian tube problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/34/8738\">",
"         Patient information: Strep throat in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/16/15619\">",
"         Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/22/3427\">",
"         Patient information: Sore throat in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tonsillectomy and adenoidectomy in children (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H258895480\">",
"      <span class=\"h1\">",
"       What is a tonsillectomy or an adenoidectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A tonsillectomy is surgery to remove the tonsils. These are areas of soft tissue in the back of the throat. An adenoidectomy is surgery to remove the adenoids. Adenoids are also areas of soft tissue in the throat. They are located higher up than the tonsils.",
"     </p>",
"     <p>",
"      Doctors can do just a tonsillectomy, just an adenoidectomy, or both. The type of surgery depends on the symptoms and other factors.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258895497\">",
"      <span class=\"h1\">",
"       Why might a child need a tonsillectomy or adenoidectomy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are a few reasons. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing &ndash; Swollen tonsils or adenoids can keep a child from breathing normally through the mouth or nose. If someone stops breathing for short periods during sleep, doctors call it &ldquo;sleep apnea.&rdquo; It can be dangerous.",
"       </li>",
"       <li>",
"        Trouble swallowing normally",
"       </li>",
"       <li>",
"        Many throat or ear infections &ndash; If other treatments do not help, a child might need surgery.",
"       </li>",
"       <li>",
"        A growth on the tonsils",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258895512\">",
"      <span class=\"h1\">",
"       What do tonsillectomy and adenoidectomy involve?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before surgery, your child&rsquo;s doctor will give you instructions about what to do. Children should not eat or drink for a certain number of hours before surgery.",
"     </p>",
"     <p>",
"      Most children can go home a few hours after surgery. The doctor will tell you if your child needs to stay overnight for any reason.",
"     </p>",
"     <p>",
"      When the surgery starts, the doctor will give your child medicine to make him or her fall asleep. Then the doctor will take out the tonsils, adenoids, or both.",
"     </p>",
"     <p>",
"      Your child might have an upset stomach and throw up for 1 or 2 days. He or she will also have a very sore throat for a few days. A child who has just an adenoidectomy usually has less pain and feels better faster after surgery.",
"     </p>",
"     <p>",
"      Children need to stay home from school for a few days after surgery. The doctor will tell you when your child can go back to school.",
"     </p>",
"     <p>",
"      Your child should avoid sports and very active play for at least 2 weeks. He or she should stay away from people with colds, coughs, and the flu for 2 weeks after surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258895527\">",
"      <span class=\"h1\">",
"       What can I do to help my child feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help your child feel better after surgery, you can give him or her:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Plenty of liquids",
"        </strong>",
"        &nbsp;&ndash; Such as water, grape juice, broth, or an &ldquo;oral rehydration solution&rdquo; (sample brand name: Pedialyte) that you buy in a store or pharmacy. Your child might not feel like drinking, but it&rsquo;s important that he or she gets enough liquids.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines",
"        </strong>",
"        &nbsp;&ndash;",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         Acetaminophen",
"        </a>",
"        &nbsp;(sample brand name: Tylenol) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        &nbsp;(sample brand names: Advil, Motrin) can help with throat pain. The correct dose depends on your child&rsquo;s weight, so ask your child&rsquo;s doctor how much to give.",
"        <br/>",
"        <br/>",
"        Do not give",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        or medicines that contain aspirin to children younger than 18 years. In children, aspirin can cause a serious problem called Reye syndrome. Aspirin also increases the risk of bleeding after surgery.",
"       </li>",
"       <li>",
"        <strong>",
"         Foods that are easy to swallow",
"        </strong>",
"        &ndash; Such as soft bread, Jell-O, mashed potatoes, pudding, and applesauce.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <strong>",
"       Do not give",
"      </strong>",
"      your child citrus juices, such as orange or grapefruit juice, and do not give your child foods that are hard, scratchy, spicy, or acidic. These juices and foods can irritate your child&rsquo;s throat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258895542\">",
"      <span class=\"h1\">",
"       When should I call my child&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After surgery, call your child&rsquo;s doctor or nurse if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has bright red blood coming from the nose or throat &ndash; A little blood in saliva or vomit is normal after surgery. If you see a lot of bright red blood, take your child to the hospital right away.",
"       </li>",
"       <li>",
"        Cannot drink liquids",
"       </li>",
"       <li>",
"        Has vomiting that does not get better",
"       </li>",
"       <li>",
"        Gets a fever",
"       </li>",
"       <li>",
"        Has a severe sore throat that doesn&rsquo;t get better or gets worse",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258895557\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=see_link\">",
"       Patient information: Anesthesia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/9/20626?source=see_link\">",
"       Patient information: Ear tubes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/45/25298?source=see_link\">",
"       Patient information: Eustachian tube problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"       Patient information: Strep throat in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"       Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=see_link\">",
"       Patient information: Sore throat in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/1/11282?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86833 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11282=[""].join("\n");
var outline_f11_1_11282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258895480\">",
"      What is a tonsillectomy or an adenoidectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258895497\">",
"      Why might a child need a tonsillectomy or adenoidectomy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258895512\">",
"      What do tonsillectomy and adenoidectomy involve?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258895527\">",
"      What can I do to help my child feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258895542\">",
"      When should I call my child&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258895557\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=related_link\">",
"      Patient information: Anesthesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/9/20626?source=related_link\">",
"      Patient information: Ear tubes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/45/25298?source=related_link\">",
"      Patient information: Eustachian tube problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_1_11283="Patient information: Ovarian cancer (The Basics)";
var content_f11_1_11283=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15417\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"          Types of abdominal hysterectomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/41/3731\">",
"         Patient information: Hysterectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/18/12579\">",
"         Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/16/6405\">",
"         Patient information: Abdominal hysterectomy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/34/41507\">",
"         Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/15/30963\">",
"         Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/63/11252\">",
"         Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/15/6386\">",
"         Patient information: Ovarian cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ovarian cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ovarian-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H455403470\">",
"      <span class=\"h1\">",
"       What is ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ovarian cancer happens when normal cells in the ovary change into abnormal cells and grow out of control. The ovaries are organs that are part of a woman&rsquo;s reproductive system. A woman&rsquo;s eggs develop in the ovaries (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Ovarian cancer occurs most often in women ages 40 to 65, and sometimes runs in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403477\">",
"      <span class=\"h1\">",
"       What are the symptoms of ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of ovarian cancer can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your stomach getting bigger",
"       </li>",
"       <li>",
"        Feeling bloated or having stomach pain",
"       </li>",
"       <li>",
"        Feeling full or having trouble eating",
"       </li>",
"       <li>",
"        Needing to urinate often",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When ovarian cancer begins to grow, some women might not notice their symptoms much. But as the cancer grows, the symptoms become worse.",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not ovarian cancer. But if you have these symptoms, you should let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403484\">",
"      <span class=\"h1\">",
"       Is there a test for ovarian cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor suspects you have ovarian cancer, he or she might order one or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Ultrasound or other imaging tests",
"        </strong>",
"        &ndash; These tests create images of the inside of the body and can show abnormal growths.",
"       </li>",
"       <li>",
"        <strong>",
"         Blood tests",
"        </strong>",
"        &ndash; A blood test called &ldquo;CA 125&rdquo; is sometimes used to help diagnose ovarian cancer.",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; The only way to know for sure if a woman has ovarian cancer is for a doctor to do surgery and remove the ovary. While the surgery is going on, another doctor will look at cells from the ovary under a microscope to check for cancer. If cancer is present, the doctor will usually continue surgery and treat the cancer by removing as much of it as possible. Most of the time, this involves doing a surgery called &ldquo;total hysterectomy with salpingo-oophorectomy&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef57901 \" href=\"UTD.htm?37/40/38534\">",
"         figure 2",
"        </a>",
"        ). For this surgery, the doctor removes the ovaries, the tubes that connect the ovaries to the uterus (fallopian tubes), and the uterus. If the cancer has spread to other nearby organs, the doctor might remove those, too.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403491\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far a cancer has spread.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403498\">",
"      <span class=\"h1\">",
"       How is ovarian cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For most women, having surgery to remove the cancer is the first part of treatment. Further treatment will depend a lot on the stage of the cancer, a woman&rsquo;s age, and her other medical problems. Some women might not need any further treatment after surgery. Other women might need further treatment that includes chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Usually, these medicines go into a vein. But sometimes they can go through a small tube into the lower part of the stomach.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403505\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant one day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to have a baby one day, tell your doctor before having treatment. Treatment for ovarian cancer usually leaves a woman unable to get pregnant. But for some women it might be possible to plan treatment so that pregnancy is still possible. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403512\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Follow up tests usually include blood tests, exams, and imaging tests. You should also watch for the symptoms listed above, because having those symptoms could mean the cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403519\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might have more surgery or chemotherapy. You might also have a medicine called targeted therapy, which can help prevent cancer growth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403526\">",
"      <span class=\"h1\">",
"       Can ovarian cancer be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If ovarian or breast cancer runs in your family, talk to your doctor. There may be things you can do to keep from getting cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403533\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for ovarian cancer involves making many choices, such as what treatment to have.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455403540\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=see_link\">",
"       Patient information: Hysterectomy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"       Patient information: Ovarian cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"       Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"       Patient information: Abdominal hysterectomy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/1/11283?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15417 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11283=[""].join("\n");
var outline_f11_1_11283=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403470\">",
"      What is ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403477\">",
"      What are the symptoms of ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403484\">",
"      Is there a test for ovarian cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403491\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403498\">",
"      How is ovarian cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403505\">",
"      What if I want to get pregnant one day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403512\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403519\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403526\">",
"      Can ovarian cancer be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403533\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455403540\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15417\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"       Types of abdominal hysterectomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=related_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=related_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=related_link\">",
"      Patient information: Hysterectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=related_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_1_11284="Miliaria rubra";
var content_f11_1_11284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Miliaria rubra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Miliaria rubra, also known as heat rash, consists of small erythematous papules and vesicles on covered portions of the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kenneth Greer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11284=[""].join("\n");
var outline_f11_1_11284=null;
var title_f11_1_11285="Prenatal ultrasound image of umbilical cord pseudocyst";
var content_f11_1_11285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of umbilical cord pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Multiple umbilical cord pseudocysts in a fetus with trisomy 18.",
"    <br>",
"     (Panel B) Color Doppler imaging depicts the vascular component of the umbilical cord.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11285=[""].join("\n");
var outline_f11_1_11285=null;
var title_f11_1_11286="Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)";
var content_f11_1_11286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11286/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11286/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11286/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11286/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11286/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11286/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/1/11286/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nucleoside analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV, also known as AZT) was the first drug to be approved for the treatment of HIV infection in 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/1\">",
"     1",
"    </a>",
"    ]. Zidovudine led to clinical benefit and immunologic improvements in patients with advanced HIV disease; however, these benefits were only transient. Subsequent clinical monotherapy trials using other nucleoside analogs led to similar disappointing results.",
"   </p>",
"   <p>",
"    This topic will address some of the early treatment trials in HIV therapy that led to a major revolution in clinical management, including the need for three-drug combination therapy for optimal clinical benefit and the identification of viral suppression as the therapeutic benchmark that is used in clinical trials today. The clinical use of combination ART is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8235948\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the early years of randomized clinical trials of HIV therapy, clinical endpoints, such as progression to AIDS and death, were the primary outcomes assessed as the major determinants of treatment efficacy. Although immunologic benefit could be determined using flow cytometry for measuring changes in CD4 cell counts, there were only crude measurements of viral load, such as p24 antigen, which only became detectable in primary infection or terminal illness. The inexorable immunologic changes that were seen, despite mono or dual therapy, were not well explained since researchers were in a very early phase of understanding of HIV pathogenesis.",
"   </p>",
"   <p>",
"    The significant breakthroughs in understanding HIV pathogenesis and its relationship to patient management included the following major advancements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of quantitative assays that measure HIV RNA, which helped to assess on-treatment responses. These assays also illustrated that HIV was replicating throughout the course of disease.",
"     </li>",
"     <li>",
"      The development of the protease inhibitor (PI) class of drugs, which led to rapid and marked declines in viremia",
"     </li>",
"     <li>",
"      The demonstration that three-drug therapy (including two different classes of drugs) was superior to dual therapy in decreasing the progression to clinical AIDS and death",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of quantitative HIV RNA assays led to a new understanding that HIV was a dynamic and prolific infection, with production of billions of virions daily and daily destruction of millions of CD4+ T cells. The introduction of the protease inhibitors also shaped the current understanding of HIV since studies of antiretroviral medications, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , demonstrated steep declines of plasma viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link&amp;anchor=H2#H2\">",
"     \"Drug resistance testing in the clinical management of HIV infection\", section on 'Contributing factors to resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8236115\">",
"    <span class=\"h1\">",
"     ANTIRETROVIRAL MEDICATIONS DISCUSSED IN THIS TOPIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following antiretroviral medications are discussed within this topic; their commonly used abbreviations and generic and trade names are listed below.",
"   </p>",
"   <p>",
"    Nucleoside reverse transcriptase inhibitors (NRTIs):",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    &nbsp; &nbsp;ZDV &nbsp; &nbsp; &nbsp; &nbsp; AZT",
"   </p>",
"   <p>",
"    Zalcitabine &nbsp; &nbsp;ddC &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hivid",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    &nbsp; &nbsp;ddI &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Videx",
"   </p>",
"   <p>",
"    Protease inhibitors (PIs):",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    &nbsp; &nbsp; &nbsp; IDV &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Crixivan",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) MONOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    (ZDV), also known as AZT, was the first drug to be approved for the treatment of HIV infection and was evaluated in symptomatic patients with advanced immunosuppression and in asymptomatic patients with CD4 cell counts &gt;500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Advanced HIV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a double-blind controlled trial in patients with a history of Pneumocystis jirovecii pneumonia (PCP) or advanced AIDS, 282 patients were stratified by CD4 cell count to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    monotherapy (250 mg every four hours) or placebo for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trial was terminated early when significantly fewer patients died (1 versus 19) in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    versus placebo arm; furthermore, significantly fewer patients developed an opportunistic infection in the treatment arm (24 versus 45 events). Anemia severe enough to require transfusions or drug discontinuation was observed significantly more often in those receiving ZDV than placebo.",
"   </p>",
"   <p>",
"    Although a statistically significant increase in CD4 cell counts was also demonstrated in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , this laboratory parameter returned to baseline in those patients with clinical AIDS compared with those with less advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Earlier HIV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Concorde and ACTG 019 trials did not demonstrate benefit of early treatment of asymptomatic patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Concorde trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concorde was a clinical trial that compared a strategy of immediate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    therapy (250 mg four times daily) with deferred therapy in 1749 asymptomatic HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a median follow-up of 3.3 years, there was no significant difference in survival with immediate or delayed therapy (92 versus 94 percent) and no difference in a combined end point of death or progression to AIDS (ie, 18 percent in both arms).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     AIDS Clinical Trial Group (ACTG) 019",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared immediate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    therapy (500 or 1500 mg daily in divided doses) versus deferred therapy in 1637 patients with an initial CD4 count &ge;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although CD4 counts declined more slowly in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , there was no significant difference in the rate of progression to AIDS or death compared with patients who had deferred therapy (3.4 versus 3.6 events per 100 person-years) and no difference in the mortality rate (1.9 versus 2.2 deaths per 100 person-years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPARISONS OF NRTI MONOTHERAPY AND DUAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the development of additional NRTIs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , zalcitabine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , additional trials assessed the efficacy of dual versus monotherapy for HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Delta trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Delta trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    monotherapy with combination therapy including zidovudine plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    or zalcitabine in 3207 patients with either symptomatic disease or in asymptomatic patients with a CD4 count below 350",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a median follow-up of 30 months, 22 percent of the patients had died. Among patients who had not previously taken",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , the risk of death was reduced in patients who received combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (HR 0.58) or zalcitabine (HR 0.68) compared with zidovudine monotherapy. Among patients with prior zidovudine exposure, there was a reduced risk of death with didanosine combination therapy (HR 0.72), but there was no significant decrease in risk with zalcitabine combination therapy.",
"   </p>",
"   <p>",
"    This trial suggested that treatment with two antiretroviral drugs was superior to monotherapy in treatment-naive patients. Among treatment-experienced patients, there was greater efficacy of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    dual therapy compared to zidovudine alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     AIDS Clinical Trial Group (ACTG) 175 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;This double-blind trial evaluated treatment with mono or dual NRTI therapy in 2467 HIV-infected patients whose CD4 counts ranged from 200 to 500",
"    <span class=\"nowrap\">",
"     cells/microL;",
"    </span>",
"    43 percent were treatment-naive [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients were randomly assigned to one of four daily regimens:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    alone; zidovudine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    ; zidovudine plus zalcitabine; or didanosine alone. The primary end point was a 50 percent decline in the CD4 cell count, development of AIDS, or death.",
"   </p>",
"   <p>",
"    Over the course of follow-up (median duration 118 weeks) there were 565 patients who reached a primary endpoint; 69 percent of these patients were in the subgroup with a history of prior ART. Compared with patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    monotherapy, the risk of progression to the primary combined end point (50 percent decline in CD4 count, AIDS, or death) was reduced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    monotherapy (HR 0.61), dual zidovudine plus didanosine (HR 0.50) and dual zidovudine plus zalcitabine (HR 0.54). The beneficial effect of zidovudine plus zalcitabine therapy was limited to those who were ART-naive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178516\">",
"    <span class=\"h2\">",
"     North American Working Group",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the introduction of the NRTI",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in 1995, another clinical trial addressed the efficacy of mono or dual NRTI therapy with random assignment of 366 patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    alone, lamivudine alone, or combination therapy with zidovudine with either low-dose or high-dose lamivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/7\">",
"     7",
"    </a>",
"    ]. Over 24 weeks, CD4 cell count increases and HIV RNA declines were significantly greater in the combination arms with a similar safety profile as in the monotherapy arms. Although resistance to lamivudine monotherapy occurred rapidly, the drug had greater potency and was better tolerated than existing NRTI options, making it ideal for combination therapy.",
"   </p>",
"   <p>",
"    This clinical trial used changes in HIV RNA levels as a primary endpoint based on retrospective data showing that viral load was an independent predictor of HIV clinical progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPARISONS OF DUAL AND TRIPLE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials compared dual nucleoside analog therapy compared to triple therapy using either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    as the protease inhibitor component.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725220\">",
"    <span class=\"h2\">",
"     Ritonavir",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725192\">",
"    <span class=\"h3\">",
"     Advanced HIV Disease Ritonavir Study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advanced HIV Disease",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    Study compared the investigational protease inhibitor ritonavir added to NRTIs to continued NRTIs alone in 1090 treatment-experienced patients with CD4 cell counts &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/10\">",
"     10",
"    </a>",
"    ]. Clinical outcomes (progression to AIDS or death) strongly favored the ritonavir-based regimens, demonstrating the clinical benefit of protease inhibitor-based therapies even in the presence of substantial drug toxicity, NRTI drug resistance, and advanced HIV disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725235\">",
"    <span class=\"h2\">",
"     Indinavir",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725213\">",
"    <span class=\"h3\">",
"     Merck 035 study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a controlled trial, 97 patients (CD4 cell count range 50 to 400",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    with prior exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    monotherapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    dual therapy, or all three drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/2\">",
"     2",
"    </a>",
"    ]. At week 24, the proportion of patients achieving viral suppression (&lt;500",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    was higher in the three-drug arm compared with the indinavir monotherapy arm (eg, 90 percent versus 43 percent); none of the patients in the dual therapy arm achieved viral suppression. In addition, CD4 cell count recovery was significantly better in the indinavir arms compared with the dual therapy arm. All regimens were well tolerated. This was the first controlled clinical trial of triple therapy for HIV demonstrating that durable suppression of HIV RNA was achievable. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     AIDS Clinical Trial Group (ACTG) 320 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AIDS Clinical Trial Group (ACTG) 320 trial compared dual NRTI therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ) with the same regimen plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    in 1156 patients who had previously received at least three months of zidovudine and had a CD4 count no greater than 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trial was stopped early when the monitoring board found significant differences between the two groups; in total, 96 patients developed AIDS or died. After a median follow-up of 38 weeks, fewer patients treated with triple therapy reached the primary combined end point of a new clinical AIDS-defining event or death (6 versus 11 percent; hazard ratio 0.50, 95% CI 0.33-0.76) and fewer patients died (1.4 versus 3.1 percent; hazard ratio 0.43, 95% CI 0.19-0.99).",
"   </p>",
"   <p>",
"    A subset of 190 randomly selected patients had measurements of HIV RNA during treatment; by week 24, the proportion of patients with plasma HIV RNA concentrations of &lt;500",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was much higher in the triple therapy arm (60 versus 9 percent).",
"   </p>",
"   <p>",
"    Importantly, the ACTG 320 trial demonstrated the clinical benefit of PI-containing triple therapy over dual NRTI treatment, even in treatment-experienced patients with advanced HIV disease. It also demonstrated the strong relationship between achieving virologic suppression and clinical outcomes. Subsequent analyses of ACTG 320 and other studies showed that virologic suppression was sustained over prolonged periods without the development of antiviral drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8236153\">",
"    <span class=\"h1\">",
"     VIRAL SUPPRESSION AS A SURROGATE ENDPOINT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACTG 320 trial was one of the last major clinical trials with HIV-related clinical endpoints and death as the primary outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/11\">",
"     11",
"    </a>",
"    ]. Most subsequent studies of antiretroviral therapy have used HIV RNA as a surrogate for antiviral activity. Several studies have shown a direct correlation between treatment-associated viral suppression and a lower risk of developing AIDS or death, thus establishing viral suppression as a surrogate therapeutic marker of drug efficacy and presumed clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11286/abstract/8,9,11-13\">",
"     8,9,11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      (ZDV, also known as AZT) was the first nucleoside reverse transcriptase inhibitor (NRTI) to be approved for the treatment of HIV infection in 1987. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant breakthroughs in HIV management included the ability to measure viremia through quantitative assays and the development of the protease inhibitors, a potent class of drugs. The combination of three drugs, using two drug classes led to significantly improved clinical outcomes with a lower risk of developing AIDS or dying. (See",
"      <a class=\"local\" href=\"#H8235948\">",
"       'General background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with advanced HIV, monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      led to decreased incidence of death and opportunistic infections. However, in asymptomatic disease, no benefit of early versus deferred zidovudine monotherapy was seen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nucleoside reverse transcriptase inhibitor (NRTI) monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In symptomatic patients with a CD4 cell count &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      dual NRTI therapy reduced the risk of AIDS or death compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      monotherapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Comparisons of NRTI monotherapy and dual therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ACTG 320 trial was a landmark study, proving that triple therapy with two NRTIs plus a protease inhibitor was superior to dual NRTI therapy alone in reducing AIDS-related complications and deaths. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Comparisons of NRTI monotherapy and dual therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ACTG 320 trial was the last study to use clinical endpoints to determine treatment efficacy; subsequent trials have used viral suppression as a surrogate laboratory marker of treatment efficacy. (See",
"      <a class=\"local\" href=\"#H8236153\">",
"       'Viral suppression as a surrogate endpoint'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/1\">",
"      Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/2\">",
"      Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/3\">",
"      Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/4\">",
"      Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1995; 333:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/5\">",
"      Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 1996; 348:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/6\">",
"      Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/7\">",
"      Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995; 333:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/8\">",
"      Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis 1996; 174:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/9\">",
"      O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/10\">",
"      Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/11\">",
"      Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/12\">",
"      Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11286/abstract/13\">",
"      Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997; 126:929.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3760 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11286=[""].join("\n");
var outline_f11_1_11286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8235948\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8236115\">",
"      ANTIRETROVIRAL MEDICATIONS DISCUSSED IN THIS TOPIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) MONOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Advanced HIV disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Earlier HIV disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Concorde trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - AIDS Clinical Trial Group (ACTG) 019",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPARISONS OF NRTI MONOTHERAPY AND DUAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Delta trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AIDS Clinical Trial Group (ACTG) 175 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1178516\">",
"      North American Working Group",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPARISONS OF DUAL AND TRIPLE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2725220\">",
"      Ritonavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2725192\">",
"      - Advanced HIV Disease Ritonavir Study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2725235\">",
"      Indinavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2725213\">",
"      - Merck 035 study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - AIDS Clinical Trial Group (ACTG) 320 trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8236153\">",
"      VIRAL SUPPRESSION AS A SURROGATE ENDPOINT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_1_11287="Clinical manifestations of Sjögren's syndrome: Exocrine gland disease";
var content_f11_1_11287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11287/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11287/contributors\">",
"     Robert Fox, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11287/contributors\">",
"     Paul Creamer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11287/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11287/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11287/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/1/11287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren&rsquo;s syndrome (SS) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function. SS occurs in a primary form not associated with other diseases and in a secondary form that complicates other rheumatic conditions. The most common disease associated with secondary SS is rheumatoid arthritis.",
"   </p>",
"   <p>",
"    In primary or secondary SS, decreased exocrine gland function leads to the &ldquo;sicca complex,&rdquo; a combination of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, a wide variety of other disease manifestations can occur in SS. The clinical manifestations of SS are divided into the exocrine gland features and the extraglandular disease features [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study of 80 patients with primary SS followed for a median of 7.5 years reported the following frequencies of clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keratoconjunctivitis sicca",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      xerostomia occurred in all patients and were the only disease manifestation in 31 percent.",
"     </li>",
"     <li>",
"      Extraglandular involvement occurred in 25 percent.",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma developed in 2.5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A series of different classification criteria have been used to define and characterize SS. Most information cited in this topic review regarding SS has relied upon the 2002 American European Consensus Group (AECG) classification criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, in 2012, a different set of criteria was proposed by the American College of Rheumatology (ACR) that differed from the AECG criteria in several respects, including the exclusion of subjective ocular or oral dryness from the ACR criteria set and the lack of a distinction between primary and secondary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, differences in estimates of the frequency and severity of various clinical manifestations may be observed that depend upon the criteria used to identify the patients included in the analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H23#H23\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of exocrine gland disease in SS will be reviewed here. The extraglandular manifestations, the classification and diagnosis, and the treatment of both sicca and extraglandular manifestations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=see_link\">",
"     \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=see_link\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXOCRINE GLAND INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major signs of exocrine gland involvement are dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia), but other manifestations may also be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keratoconjunctivitis sicca &mdash; Keratoconjunctivitis sicca (KCS) is the preferred term (over &ldquo;xerophthalmia&rdquo;) when referring to the ocular dryness associated with SS. The ocular symptoms of dry eyes are irritation, grittiness, and a foreign body sensation.",
"     </li>",
"     <li>",
"      Xerostomia &mdash; The oral dryness of SS leads to difficulty swallowing dry food such as crackers without drinking liquids (",
"      <a class=\"graphic graphic_picture graphicRef51074 \" href=\"UTD.htm?11/58/12193\">",
"       picture 1",
"      </a>",
"      ). Oral dryness is associated with an increased rate of dental caries and periodontal complications (",
"      <a class=\"graphic graphic_picture graphicRef53927 \" href=\"UTD.htm?7/18/7456\">",
"       picture 2",
"      </a>",
"      ) and often with a decrease in the sense of taste and a change in oral flora, including an increase in oral candidiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/8-10\">",
"       8-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The KCS and xerostomia of SS are caused by immune-mediated inflammation directed against the exocrine glands of the eye and mouth. The histologic features include extensive lymphocytic infiltration, accompanied by glandular and ductal atrophy (",
"      <a class=\"graphic graphic_picture graphicRef79996 \" href=\"UTD.htm?17/10/17577\">",
"       picture 3",
"      </a>",
"      ). This lymphocytic infiltration is organized in germinal center-like structures [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salivary gland enlargement &mdash; The parotid, submandibular, and other salivary glands may all undergo hypertrophy in SS (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69831 \" href=\"UTD.htm?23/41/24208\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef85931 \" href=\"UTD.htm?37/15/38130\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other &mdash; Exocrine gland involvement in the skin and upper airway tract may lead to xerosis, a nonspecific cough, and other symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. Vaginal dryness may be associated with dyspareunia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/15-18\">",
"       15-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Xerosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Keratoconjunctivitis sicca",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratoconjunctivitis sicca (KCS), caused by a reduction in the aqueous component of tears, is one of the most common causes of dry eyes (",
"    <a class=\"graphic graphic_table graphicRef77821 \" href=\"UTD.htm?37/39/38524\">",
"     table 1",
"    </a>",
"    ). The alternative name of &ldquo;dysfunctional tear syndrome,&rdquo; proposed at a conference of ophthalmological experts, is not widely accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    KCS usually presents insidiously over a period of several years. The symptoms vary and are often worse in the evening. Affected patients may complain of a &ldquo;gritty&rdquo; or &ldquo;sandy&rdquo; feeling in their eyes rather than describe &ldquo;dryness.&rdquo; A paradoxical finding in KCS is that, despite profound ocular dryness, an inability to cry is not a common symptom.",
"   </p>",
"   <p>",
"    Other symptoms include irritation, itching, photophobia, and the accumulation of thick, rope-like strands (mucus filaments) at the inner canthus. Mucus filaments are particularly present upon awakening. Complications of KCS include corneal ulceration and infection of the eyelids.",
"   </p>",
"   <p>",
"    Physical examination may reveal one or more of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Punctate conjunctival and corneal damage, as detected by Rose Bengal or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      staining (",
"      <a class=\"graphic graphic_picture graphicRef59477 \" href=\"UTD.htm?17/17/17695\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Evidence of reduced tear production, as detected by a Schirmer test",
"     </li>",
"     <li>",
"      Mucus filaments",
"     </li>",
"     <li>",
"      Dilation of the bulbar conjunctival vessels",
"     </li>",
"     <li>",
"      Dullness of the conjunctiva and cornea",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Xerostomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of SS on the oral cavity result from chronic salivary hypofunction. Dry mouth is a common symptom, particularly in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/20\">",
"     20",
"    </a>",
"    ], but objective evidence of reduced salivary flow is less frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/21\">",
"     21",
"    </a>",
"    ]. Other causes of dry mouth are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77821 \" href=\"UTD.htm?37/39/38524\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Confirmation that the symptoms of dryness are due to SS often requires a salivary gland biopsy. This procedure is performed routinely on an outpatient basis. However, salivary gland biopsy is not necessary in all patients. Primary SS is often associated with autoantibodies directed against either the",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     La/SSB",
"    </span>",
"    antigens. The combination of clinical features consistent with SS and the finding of",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies generally precludes the need for salivary gland biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may complain directly of oral dryness or of complications such as dysphagia, adherence of food to buccal surfaces, problems with dentures, changes in taste, or an inability to eat dry food or to speak continuously for long periods.",
"   </p>",
"   <p>",
"    Chronic xerostomia may result in a number of complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dental caries, which occur in up to 65 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gingival recession [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Oral candidiasis, which may occur in over one-third of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/24-26\">",
"       24-26",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H2801192\">",
"       'Oral candidiasis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Other types of oral infections, such as bacterial infections of Stensen's duct (",
"      <a class=\"graphic graphic_picture graphicRef52846 \" href=\"UTD.htm?10/11/10431\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Laryngotracheal reflux, which may lead to frequent throat clearing, cough, substernal pain, and nocturnal awakening that simulates panic attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Laryngotracheal reflux in SS is the result of decreased salivary flow, of the absence of the normal gastric acid buffer, and of reflux of gastric acid into the esophagus and trachea.",
"     </li>",
"     <li>",
"      Chronic esophagitis, also due to impaired clearance of acid and lack of the buffering effects of saliva (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"       \"Pathophysiology of reflux esophagitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Weight loss, due to difficulty with chewing and deglutition",
"     </li>",
"     <li>",
"      Nocturia, which results from attempts on the part of the patients to counter dry mouth by drinking copious volumes of fluids",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2801192\">",
"    <span class=\"h3\">",
"     Oral candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral candidiasis is a common complication of SS; it may occur in over one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Symptoms include a painful mouth, sometimes with a burning sensation, and sensitivity to spicy or acidic foods [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/29\">",
"     29",
"    </a>",
"    ]. Findings in SS patients with oral candidiasis are typically those of erythematous or chronic atrophic candidiasis, including diffuse or patchy erythema, typically affecting the hard palate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation of oral candidiasis in SS is in contrast to the typically fluffy white exudates which predominate in patients with human immunodeficiency virus or with immunosuppression due to chemotherapy. The tongue, buccal mucosa, palate, lips, and corners of the lips may be affected, and there may be loss of tongue papillae. Angular cheilitis and atrophic changes of the buccal mucosa are common manifestations in SS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\", section on 'Oropharyngeal candidiasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral candidiasis is often facilitated by the wearing of dentures (&ldquo;denture stomatitis&rdquo;), which may need to be removed to determine whether candidiasis is present and to assess the response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/30\">",
"     30",
"    </a>",
"    ]. Oral candidiasis is particularly frequent following antibiotic treatment or the use of glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Salivary gland enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland enlargement occurs in 30 to 50 percent of patients with SS at some point during the course of the disease. The glands are usually firm, diffuse, and nontender. These changes are most obvious in the parotid glands, but the submandibular glands may be affected to the same degree (",
"    <a class=\"graphic graphic_picture graphicRef80350 \" href=\"UTD.htm?27/39/28272\">",
"     picture 7",
"    </a>",
"    ). Salivary gland enlargement may be either chronic or episodic, with swelling followed by reduction over a few weeks.",
"   </p>",
"   <p>",
"    A particularly hard or nodular gland may suggest a neoplasm. The differential diagnosis of enlarged parotid glands is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef77821 \" href=\"UTD.htm?37/39/38524\">",
"     table 1",
"    </a>",
"    ). Radiographs obtained after instilling contrast into the salivary ducts may reveal sialectasis and pruning of the peripheral branches (",
"    <a class=\"graphic graphic_picture graphicRef54109 \" href=\"UTD.htm?9/24/9600\">",
"     picture 8",
"    </a>",
"    ). Magnetic resonance imaging may show diffuse enlargement of the glands with or without sialectasis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58074 graphicRef80648 \" href=\"UTD.htm?24/18/24869\">",
"     image 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lacrimal gland enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacrimal gland enlargement can also occur in SS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3651248\">",
"    <span class=\"h2\">",
"     Genitourinary manifestations in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal dryness with associated dyspareunia is a common symptom in women with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/31\">",
"     31",
"    </a>",
"    ]. This symptom is often complicated by bacterial and candidal infections. Non-exocrine involvement may be manifested as interstitial cystitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other genitourinary disorders that are noted more frequently in women with SS than in healthy women include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/18,32-35\">",
"     18,32-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Episodes of amenorrhea lasting for more than three months",
"     </li>",
"     <li>",
"      Menorrhagia or metrorrhagia",
"     </li>",
"     <li>",
"      Endometriosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3651256\">",
"    <span class=\"h2\">",
"     Upper airways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of exocrine glands in the upper airways leads to symptoms related to the nose, sinuses, and posterior pharynx in 50 to 70 percent of patients with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/36\">",
"     36",
"    </a>",
"    ]. Such patients can have recurrent nonallergic rhinitis and sinusitis.",
"   </p>",
"   <p>",
"    The most common symptom of laryngeal, tracheal, and bronchial involvement is a dry cough, which may be persistent and irritating. If the patient does not have other features of SS, the diagnosis may be missed, and the patient may be treated incorrectly for asthma or bronchitis. Only 20 percent of affected patients have abnormalities that can be identified by rhinoscopy or indirect laryngoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11287/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchial dryness becomes especially important in two situations. First, in the presence of upper airway infections, there is a tendency to develop mucus plug inspissation. This may be exacerbated by over-the-counter cold preparations that contain anticholinergic drugs. Second, mucus plugs can occur postoperatively, as a result of anticholinergic drugs given by the anesthetist and of the dehydrating effects of the operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12141883\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sj&ouml;gren&rsquo;s syndrome (SS) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function. SS occurs in primary and secondary forms. The major signs of exocrine gland involvement are dry eyes (keratoconjunctivitis sicca, KCS) and dry mouth (xerostomia), caused by immune-mediated inflammation directed against the exocrine glands of the eye and mouth. Histologic features include extensive lymphocytic infiltration, with glandular and ductal atrophy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Exocrine gland involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      KCS, caused by a reduction in the aqueous component of tears, usually presents insidiously over a period of several years. Patients may complain of a &ldquo;gritty&rdquo; or &ldquo;sandy&rdquo; feeling in their eyes, especially at night, rather than describe &ldquo;dryness.&rdquo; Physical examination may include punctate conjunctival and corneal damage and evidence of reduced tear production. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Keratoconjunctivitis sicca'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Xerostomia results from chronic salivary hypofunction. Dry mouth is a common symptom, particularly in older adults, but objective evidence of reduced salivary flow is less frequent. Patients may also complain of dysphagia, adherence of food to buccal surfaces, problems with dentures, changes in taste, or an inability to eat dry food or to speak continuously for long periods. Chronic complications include dental caries and oral candidiasis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Xerostomia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2801192\">",
"       'Oral candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Salivary gland enlargement may be either chronic or episodic, and glands are usually firm, diffuse, and nontender. It most often affects the parotid glands, but the submandibular glands may be similarly involved. A particularly hard or nodular gland may suggest a neoplasm. Lacrimal gland enlargement can also occur in SS. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Salivary gland enlargement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Lacrimal gland enlargement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal dryness with associated dyspareunia may be complicated by bacterial and candidal infections. Non-exocrine involvement may include interstitial cystitis, and menstrual abnormalities and endometriosis may occur. (See",
"      <a class=\"local\" href=\"#H3651248\">",
"       'Genitourinary manifestations in women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upper airways involvement may cause recurrent nonallergic rhinitis and sinusitis and dry cough. (See",
"      <a class=\"local\" href=\"#H3651256\">",
"       'Upper airways'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/1\">",
"      Ramos-Casals M, Tzioufas AG, Font J. Primary Sj&ouml;gren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/2\">",
"      Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis 1999; 58:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/3\">",
"      Asmussen K, Andersen V, Bendixen G, et al. A new model for classification of disease manifestations in primary Sj&ouml;gren's syndrome: evaluation in a retrospective long-term study. J Intern Med 1996; 239:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/4\">",
"      Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sj&ouml;gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/5\">",
"      Vitali C. Classification criteria for Sj&ouml;gren's syndrome. Ann Rheum Dis 2003; 62:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/6\">",
"      Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sj&ouml;gren's syndrome: a data-driven, expert consensus approach in the Sj&ouml;gren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/7\">",
"      Malladi AS, Sack KE, Shiboski SC, et al. Primary Sj&ouml;gren's syndrome as a systemic disease: a study of participants enrolled in an international Sj&ouml;gren's syndrome registry. Arthritis Care Res (Hoboken) 2012; 64:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/8\">",
"      Schi&oslash;dt M, Christensen LB, Petersen PE, Thorn JJ. Periodontal disease in primary Sj&ouml;gren's syndrome. Oral Dis 2001; 7:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/9\">",
"      Wu AJ. The oral component of Sj&ouml;gren's syndrome: pass the scalpel and check the water. Curr Rheumatol Rep 2003; 5:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/10\">",
"      Soto-Rojas AE, Villa AR, Sifuentes-Osornio J, et al. Oral candidiasis and Sj&ouml;gren's syndrome. J Rheumatol 1998; 25:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/11\">",
"      Jonsson MV, Skarstein K, Jonsson R, Brun JG. Serological implications of germinal center-like structures in primary Sj&ouml;gren's syndrome. J Rheumatol 2007; 34:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/12\">",
"      Roguedas AM, Misery L, Sassolas B, et al. Cutaneous manifestations of primary Sj&ouml;gren's syndrome are underestimated. Clin Exp Rheumatol 2004; 22:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/13\">",
"      Provost TT, Watson R. Cutaneous manifestations of Sj&ouml;gren's syndrome. Rheum Dis Clin North Am 1992; 18:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/14\">",
"      Bernacchi E, Bianchi B, Amato L, et al. Xerosis in primary Sj&ouml;gren syndrome: immunohistochemical and functional investigations. J Dermatol Sci 2005; 39:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/15\">",
"      Skopouli FN, Papanikolaou S, Malamou-Mitsi V, et al. Obstetric and gynaecological profile in patients with primary Sj&ouml;gren's syndrome. Ann Rheum Dis 1994; 53:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/16\">",
"      Lehrer S, Bogursky E, Yemini M, et al. Gynecologic manifestations of Sj&ouml;gren's syndrome. Am J Obstet Gynecol 1994; 170:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/17\">",
"      Marchesoni D, Mozzanega B, De Sandre P, et al. Gynaecological aspects of primary Sjogren's syndrome. Eur J Obstet Gynecol Reprod Biol 1995; 63:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/18\">",
"      Mulherin DM, Sheeran TP, Kumararatne DS, et al. Sj&ouml;gren's syndrome in women presenting with chronic dyspareunia. Br J Obstet Gynaecol 1997; 104:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/19\">",
"      Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/20\">",
"      Schein OD, Hochberg MC, Mu&ntilde;oz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999; 159:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/21\">",
"      Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: the SEE project. Salisbury Eye Evaluation. J Rheumatol 1998; 25:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/22\">",
"      Daniels TE, Silverman S Jr, Michalski JP, et al. The oral component of Sj&ouml;gren's syndrome. Oral Surg Oral Med Oral Pathol 1975; 39:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/23\">",
"      Rhodus NL, Michalowicz BS. Periodontal status and sulcular Candida albicans colonization in patients with primary Sj&ouml;gren's Syndrome. Quintessence Int 2005; 36:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/24\">",
"      van der Reijden WA, Vissink A, Veerman EC, Amerongen AV. Treatment of oral dryness related complaints (xerostomia) in Sj&ouml;gren's syndrome. Ann Rheum Dis 1999; 58:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/25\">",
"      Rhodus NL, Bloomquist C, Liljemark W, Bereuter J. Prevalence, density, and manifestations of oral Candida albicans in patients with Sj&ouml;gren's syndrome. J Otolaryngol 1997; 26:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/26\">",
"      Tapper-Jones L, Aldred M, Walker DM. Prevalence and intraoral distribution of Candida albicans in Sj&ouml;gren's syndrome. J Clin Pathol 1980; 33:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/27\">",
"      Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sj&ouml;gren's syndrome. Curr Rheumatol Rep 2003; 5:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/28\">",
"      Postma GN, Belafsky PC, Aviv JE, Koufman JA. Laryngopharyngeal reflux testing. Ear Nose Throat J 2002; 81:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/29\">",
"      Soto-Rojas AE, Villa AR, Sifuentes-Osornio J, et al. Oral manifestations in patients with Sj&ouml;gren's syndrome. J Rheumatol 1998; 25:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/30\">",
"      Hernandez YL, Daniels TE. Oral candidiasis in Sj&ouml;gren's syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol 1989; 68:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/31\">",
"      Haga HJ, Gjesdal CG, Irgens LM, Ostensen M. Reproduction and gynaecological manifestations in women with primary Sj&ouml;gren's syndrome: a case-control study. Scand J Rheumatol 2005; 34:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/32\">",
"      Fukaya E, Watanabe H, Kobayashi H, et al. A case of interstitial cystitis accompanying Sj&ouml;gren's syndrome. Mod Rheumatol 2005; 15:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/33\">",
"      van de Merwe JP, Yamada T, Sakamoto Y. Systemic aspects of interstitial cystitis, immunology and linkage with autoimmune disorders. Int J Urol 2003; 10 Suppl:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/34\">",
"      Lee KL, Chen MY, Yeh JH, et al. Lower urinary tract symptoms in female patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/35\">",
"      Van de Merwe J, Kamerling R, Arendsen E, et al. Sj&ouml;gren's syndrome in patients with interstitial cystitis. J Rheumatol 1993; 20:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11287/abstract/36\">",
"      Freeman SR, Sheehan PZ, Thorpe MA, Rutka JA. Ear, nose, and throat manifestations of Sj&ouml;gren's syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol 2005; 34:20.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5607 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11287=[""].join("\n");
var outline_f11_1_11287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12141883\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXOCRINE GLAND INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Keratoconjunctivitis sicca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Xerostomia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2801192\">",
"      - Oral candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Salivary gland enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lacrimal gland enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3651248\">",
"      Genitourinary manifestations in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3651256\">",
"      Upper airways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12141883\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5607\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5607|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/41/24208\" title=\"diagnostic image 1\">",
"      Parotid enlarge SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/38/42607\" title=\"diagnostic image 2A\">",
"      Parotid enlargement MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/51/13105\" title=\"diagnostic image 2B\">",
"      Parotid gland sialectasis MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5607|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/58/12193\" title=\"picture 1\">",
"      Dry tongue in SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/18/7456\" title=\"picture 2\">",
"      Dental caries in SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/10/17577\" title=\"picture 3\">",
"      Lip gland biopsy in Sjogrens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/15/38130\" title=\"picture 4\">",
"      Sjogrens syndrome parotid gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/17/17695\" title=\"picture 5\">",
"      Rose Bengal stain in Sjogrens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/11/10431\" title=\"picture 6\">",
"      Stensens duct infxn SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/39/28272\" title=\"picture 7\">",
"      Parotid enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/24/9600\" title=\"picture 8\">",
"      Sialogram submandibular gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5607|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/39/38524\" title=\"table 1\">",
"      Differential dx Sjogrens synd",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=related_link\">",
"      Treatment of dry eyes in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=related_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_1_11288="Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients";
var content_f11_1_11288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11288/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11288/contributors\">",
"     Charles A Herzog, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11288/contributors\">",
"     J Michael Mangrum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11288/contributors\">",
"     Rod Passman, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11288/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11288/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/1/11288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients are at extraordinarily high risk for death. In 2008, the annual mortality rate for prevalent United States dialysis patients was 200",
"    <span class=\"nowrap\">",
"     deaths/1000",
"    </span>",
"    patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac disease is the major cause of death, accounting for about 40 percent of all-cause mortality in patients receiving either hemodialysis or peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States Renal Data System (USRDS) database, the single largest specific cause of death is attributed to arrhythmic mechanisms or sudden cardiac arrest (SCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and evaluation of SCA and sudden cardiac death (SCD) in the dialysis population are provided in this topic review. Detailed discussions of treatment and prevention of SCA and SCD in dialysis patients and in patients without kidney disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=see_link\">",
"     \"Treatment and prevention of sudden cardiac arrest in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, the term \"sudden cardiac death\" is commonly used to describe sudden cardiac arrest (SCA) in the setting of heart disease (although some have structurally normal hearts) with cessation of cardiac function, whether or not resuscitation or spontaneous reversion occurs.",
"   </p>",
"   <p>",
"    Previously, the term SCD has been used even if a patient were successfully resuscitated. Such cases have been referred to as \"aborted SCD\" or \"resuscitated SCD,\" and patients who experienced such events were said to be \"sudden death survivors.\" Clearer and more rational definitions of SCA and SCD were proposed in 2006 by the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/2\">",
"     2",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp;\"[Sudden] cardiac arrest is the sudden cessation of cardiac activity so that the victim becomes unresponsive, with no normal breathing and no signs of circulation. If corrective measures are not taken rapidly, this condition progresses to sudden death. Cardiac arrest should be used to signify an event as described above, that is reversed, usually by CPR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    defibrillation or cardioversion, or cardiac pacing. Sudden cardiac death should not be used to describe events that are not fatal.\"",
"   </p>",
"   <p>",
"    Except where noted, we will use the terms SCA and SCD as defined in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    document. However, most of the available epidemiologic data were published prior to this standardization and are therefore based upon different standards.",
"   </p>",
"   <p>",
"    In the USRDS database, the cause of death attributed to arrhythmic mechanisms is noted in the CMS death notification form 2746 by either \"cardiac",
"    <span class=\"nowrap\">",
"     arrest/cause",
"    </span>",
"    unknown\" or arrhythmia. Based upon this definition, arrhythmias may therefore be responsible for [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      58 percent of all cardiac deaths or 25 percent of all-cause mortality in peritoneal dialysis patients",
"     </li>",
"     <li>",
"      64 percent of all cardiac deaths or 27 percent of all-cause mortality in hemodialysis patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, death attributed to arrhythmias that is based entirely upon the CMS death notification form has obvious limitations and may be inaccurate. Thus, in addition to this definition, the USRDS Cardiovascular Special Studies Center (CVSSC) has used a more complex method in the 2006 USRDS annual data report that incorporates cause of death in the context of death location (eg, a patient succumbing to myocardial infarction on an ambulance run would be identified as sustaining SCD) and excludes patients with deaths occurring in the setting of sepsis, malignancy, hyperkalemia, and importantly, withdrawal from dialysis. Using this method, it has been estimated that 29.7 percent of deaths in prevalent dialysis patients are related to SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We feel that the overall best current estimate is that SCD is responsible for",
"    <strong>",
"     27 &plusmn; 2",
"    </strong>",
"    percent of all-cause mortality in dialysis patients. Similar findings on the relative contribution (22 to 26 percent) of sudden death to all-cause mortality in dialysis patients have been reported in multiple studies including HEMO, 4D trial, the CHOICE cohort, and the Dialysis Outcomes and Practice Patterns Study (DOPPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that the annual mortality rate for prevalent United States dialysis patients was 200",
"    <span class=\"nowrap\">",
"     deaths/1000",
"    </span>",
"    patient-years in 2008, the rate due to SCD is approximately 54",
"    <span class=\"nowrap\">",
"     deaths/1000",
"    </span>",
"    patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/1\">",
"     1",
"    </a>",
"    ]. The CVSSC has also previously estimated that the rate of SCD for period prevalent dialysis patients in 2002 was 6.9 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/3\">",
"     3",
"    </a>",
"    ] it is noteworthy that there has been a slow, steady decline in the overall cardiac mortality rate over time in the US dialysis population, and this finding is reflected in the most current estimate of the SCD rate in dialysis patients. One possible explanation is the recent increase in the use of &ldquo;evidence-based therapies&rdquo; (including beta-blockers) in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/1\">",
"     1",
"    </a>",
"    ]. In the CHOICE cohort, it was 37 SCD",
"    <span class=\"nowrap\">",
"     events/1000",
"    </span>",
"    years (which excluded in-hospital deaths, potentially under-estimating the \"true\" frequency of SCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This rate is significantly higher than that observed in the general population. In one population-based study, for example, the overall incidence of out-of-hospital cardiac arrest was 1.89 per 1000 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/9\">",
"     9",
"    </a>",
"    ]. The risk for prevalent dialysis patients is roughly comparable to that observed in patients in the general population with a history of an adverse cardiovascular event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also an enhanced risk of SCD in the first hemodialysis session of the week. Compared with the average risk of SCD, there is a 50 percent increased frequency of sudden cardiac death on Monday (for patients dialyzing Monday, Wednesday, and Friday); and on Tuesday (for patients having hemodialysis Tuesday, Thursday, and Saturday) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, one study reported a threefold increased risk of sudden death in the 12 hours before the end of the long weekend interval and a 1.7-fold increased risk of SCD in the 12 hours starting with the dialysis procedure following this long interval [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general as well as the dialysis population, most SCA events are believed to be due to ventricular arrhythmias; that is, ventricular tachycardia (VT) or ventricular fibrillation (VF). A minority may be due to bradyarrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although SCA can occur in patients with structurally normal hearts, most patients with SCA have some form of underlying heart disease. A triggering event or condition interacts with the underlying substrate to produce the fatal arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many triggers have been identified, acute myocardial ischemia is felt to be the most common initiating event in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/13\">",
"     13",
"    </a>",
"    ]. As will be discussed, the ESRD patient has some unique factors that can both alter the underlying substrate as well as trigger ventricular arrhythmic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, abnormalities of the coronary arteries, myocardium, and cardiac conduction system are the most common underlying causes of the life-threatening arrhythmias that result in SCA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/59/954?source=see_link\">",
"     \"Valvular heart disease in patients with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Predictors of SCD among hemodialysis patients were evaluated using data from the HEMO study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/14\">",
"     14",
"    </a>",
"    ]. Among 1745 enrolled hemodialysis patients, 808 died over a median follow-up of 2.5 years, 22 percent of which were due to SCD. Age, diabetes, peripheral vascular disease, ischemic heart disease, a low serum creatinine (reflecting decreased muscle mass and poor nutrition), and an elevated alkaline phosphatase predicted a higher risk for SCD. Traditional cardiovascular risk factors such as smoking and cholesterol did not, but risks conferred by these factors may have been incorporated into the overall increased risk associated with ischemic heart disease. This study did not adjust for dialysis-related risk factors (such as potassium dialysate) nor for other known risk factors such as left ventricular hypertrophy. The major results of the HEMO study are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link&amp;anchor=H11#H11\">",
"     \"Kt/V and the adequacy of hemodialysis\", section on 'HEMO study'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief overview of the more important abnormalities found in the dialysis population that may underlie their increased incidence of SCA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive coronary artery disease is likely an important contributor to SCA. However, data from the USRDS CVSSC have found an unexplained high mortality due to arrhythmic mechanisms after successful coronary revascularization, suggesting that other factors must be significant [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. In the dialysis population, for example, there was a two-year mortality of 48 and 43 percent after nondrug eluting coronary artery stents and coronary artery bypass surgery (CABG) incorporating internal mammary graft use, respectively. The annual mortality attributed to arrhythmic mechanisms was 8.5 and 7 percent after stenting and CABG, respectively, which is higher than that observed in the general population. This implies that reliance solely upon ameliorating myocardial ischemia by coronary revascularization may be an inadequate clinical strategy for the prevention of SCD in dialysis patients.",
"     </li>",
"     <li>",
"      There is a markedly increased incidence of myocardial abnormalities, such as left ventricular hypertrophy (approximately 75 percent of dialysis patients) and alterations in myocardial ultrastructure and function (including endothelial dysfunction, interstitial fibrosis, decreased perfusion reserve, and diminished ischemia tolerance). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"       \"Myocardial dysfunction in end-stage renal disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"       \"Hypertension in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid electrolyte shifts during hemodialysis sessions and the presence of hyperkalemia due to renal failure increase the risk of arrhythmias. This enhanced risk is not surprising given the profound fluid and electrolyte derangements before hemodialysis and the physiologic demands of the hemodialysis session. The nonphysiologic nature of conventional thrice-weekly hemodialysis sessions may further increase the risk of SCA. This is supported by the observational data previously mentioned showing an increased risk surrounding the first hemodialysis session of the week. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      End-stage renal disease alone is a primary promoter of an increased risk for SCA. This is supported indirectly by findings that the risk of cardiac arrest is related to increased dialysis vintage (ie, duration of renal replacement therapy). In a USRDS cohort study of all incident United States dialysis patients (1995 to 1999) surviving at least one year after dialysis initiation, the rate of cardiac arrest progressively rose from 93",
"      <span class=\"nowrap\">",
"       events/1000",
"      </span>",
"      patient-years at two years after dialysis initiation to 164",
"      <span class=\"nowrap\">",
"       events/1000",
"      </span>",
"      patient-years at five years after dialysis initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The interplay between the type of renal replacement therapy and dialysis vintage appears to have an impact upon the risk of SCA, with the relative hazard of cardiac arrest in hemodialysis compared to peritoneal dialysis varying with time after initiation of renal replacement therapy. The rate of cardiac arrest is about 50 percent higher in hemodialysis patients three months after dialysis initiation, but they are similar at two years. Three years after dialysis initiation, the rate of cardiac arrest is higher in peritoneal dialysis patients (",
"      <a class=\"graphic graphic_figure graphicRef81852 \" href=\"UTD.htm?30/33/31262\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H203921\">",
"    <span class=\"h2\">",
"     Risk factors related to dialysis prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors related to the dialysis prescription were identified in two large cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]. In one case-control study of 43,200 patients, low potassium dialysate (&lt;2.0",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    was an independent risk factor for sudden cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/18\">",
"     18",
"    </a>",
"    ]. The increased risk associated with low potassium dialysate was greatest at lower levels of predialysis serum potassium. Increased ultrafiltration volume and low calcium dialysate were also linked to sudden cardiac arrest in this study. Compared with dialysate potassium &ge;3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    dialysate potassium concentrations &le;1.5 and &le;2.0-2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    were associated with increased risk of SCD (HRs of 1.39, [95% CI 1.12-1.74] and 1.17 [95% CI 1.01-1.37], respectively). The magnitude of the association of SCD with dialysis potassium &le;1.5 was greater among patients with serum potassium &lt;5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    In DOPPS, among 37,765 participants, sudden cardiac death (SCD) was associated with a treatment time less than 3.5 hours, (hazard ratio (HR) 1.13, 95% CI 1.00-1.27), ultrafiltration volume greater than 5.7 percent of postdialysis weight (HR 1.15, 95% CI 1.00-1.32), and",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    less than 1.2 (HR 1.06, 95% CI 1.00-1.12) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    These observational studies suggest that avoiding these prescriptions when possible may reduce the risk of sudden cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prevention of sudden cardiac arrest in dialysis patients\", section on 'General measures unique to dialysis patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with and without ESRD, most individuals suffering from SCA become unconscious within seconds to minutes as a result of insufficient cerebral blood flow. There are usually no premonitory symptoms. Symptoms, if present, are nonspecific and include chest discomfort, palpitations, shortness of breath, and weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Survivor of SCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, the evaluation of the survivor of SCA includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identification and treatment of acute reversible causes",
"     </li>",
"     <li>",
"      Evaluation for structural heart disease",
"     </li>",
"     <li>",
"      In patients without obvious arrhythmic triggers or cardiac structural abnormalities, an evaluation for primary electrical diseases",
"     </li>",
"     <li>",
"      Neurologic and psychologic assessment",
"     </li>",
"     <li>",
"      In selected patients with a suspected or confirmed heritable syndrome, evaluation of family members",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation in the dialysis patient who survives SCA is generally the same as that in the patient without renal failure. However, close attention should be paid to the presence of myocardial dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia (since they are so common), the possibility of improper medication dosing in the patient with renal failure, and the circumstances associated with the event, particularly if it occurred during",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surrounding a hemodialysis session.",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since both myocardial ischemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysfunction are relatively common in the dialysis patient, their presence, either alone or in combination, may markedly enhance the risk of SCA. However, retrospective analysis has shown that 71 percent of dialysis patients who died of SCD had either normal or only mild to moderate LV dysfunction, suggesting that other factors may underlie SCA in many dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Identification of the high risk dialysis patient'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increased electrical instability resulting in SCA may have been due to fluid shifts, autonomic",
"      <span class=\"nowrap\">",
"       imbalance/increased",
"      </span>",
"      sympathetic activity (including sleep apnea),",
"      <span class=\"nowrap\">",
"       acid/base",
"      </span>",
"      disturbances, and electrolyte abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/18,21-27\">",
"       18,21-27",
"      </a>",
"      ]. An increased risk of cardiac arrest may be particularly associated with a low potassium concentration in the dialysate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"       \"Acute complications during hemodialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment and prevention of sudden cardiac arrest in dialysis patients\", section on 'Primary prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Improper dosing of certain medications may predispose the patient with renal failure to",
"      <span class=\"nowrap\">",
"       brady/tachyarrhythmias",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proarrhythmic effects, thereby causing SCA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"       \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One study reported that low predialysis serum potassium (&lt;4.3",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      was associated with an increased mortality hazard in hemodialysis patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , suggesting that even low &ldquo;normal&rdquo; potassium levels may enhance the pro-arrhythmic risk of digoxin [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/28\">",
"       28",
"      </a>",
"      ]. In this study, the mortality risk associated with digoxin was attenuated in dialysis patients with serum potassium &gt;4.6",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Digoxin should be used with extreme caution in such patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Identification of the high risk dialysis patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, it is known that reduced left ventricular (LV) function is the strongest predictor of SCA. Clinically, the presence of heart failure also identifies patients who are at high risk of SCA perhaps by additional arrhythmogenic factors, such as activation of the neurohormonal cascade and electrolyte shifts.",
"   </p>",
"   <p>",
"    Identification of the high risk patient is most useful if therapy can provide significant benefits. In the nondialysis population, most primary prevention implantable cardioverter-defibrillator (ICD) trials have shown significant improvement in survival in the following high risk groups who received ICDs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The earlier primary prevention trials enrolled nondialysis patients with decreased systolic function, prior myocardial infarction, nonsustained ventricular tachycardia, and positive electrophysiology (EP) study for induction of ventricular tachycardia.",
"     </li>",
"     <li>",
"      In later trials, enrollment did not require nonsustained VT or positive EP studies. Instead, enrollment was based upon decreased systolic function",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heart failure. In addition, nonischemic cardiomyopathy patients were included.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in the nondialysis population, primary prevention ICD trials have principally demonstrated survival",
"    <strong>",
"     improvement",
"    </strong>",
"    in groups with decreased systolic function who receive ICDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it is unclear if dialysis patients with decreased systolic function also receive survival benefits with ICD. There are no prospective studies that have examined this issue, although retrospective studies suggest some benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prevention of sudden cardiac arrest in dialysis patients\", section on 'Primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, despite the very high annual mortality from SCD, the dialysis patient with reduced LV function is not typical of the general dialysis population. Fifteen percent or fewer",
"    <strong>",
"    </strong>",
"    dialysis patients have significantly decreased LV function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In the largest study to date, among 1254 consecutive patients starting hemodialysis in Japan, 5 percent had LV ejection fractions of less than 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, other unique",
"    <span class=\"nowrap\">",
"     factors/circumstances",
"    </span>",
"    may contribute to the general increased risk of SCA in ESRD patients in dialysis. Possibilities include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is additional substrate (myocardial) modification such as interstitial fibrosis due to chronic uremia, microvascular disease or endothelial dysfunction, increased",
"      <span class=\"nowrap\">",
"       calcium/phosphate",
"      </span>",
"      deposition, and significant left ventricular hypertrophy due to hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/32-37\">",
"       32-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased electrical instability may be present due to fluid shifts, autonomic",
"      <span class=\"nowrap\">",
"       imbalance/increased",
"      </span>",
"      sympathetic activity (including sleep apnea), inflammatory state,",
"      <span class=\"nowrap\">",
"       acid/base",
"      </span>",
"      disturbances,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      electrolyte abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/18,21-27,38\">",
"       18,21-27,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that the increased risk of ventricular arrhythmias in ESRD patients is due to a combination of these many interacting factors (",
"    <a class=\"graphic graphic_figure graphicRef63859 \" href=\"UTD.htm?33/9/33949\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, while an ejection fraction of less than 35 to 40 percent is considered the major risk factor for SCA in nondialysis patients, it is likely that more mild LV dysfunction imparts a greater risk of cardiovascular events in the dialysis population, regardless of the etiology and despite optimal management. As an example, one study found that the best predictor of SCD risk in peritoneal dialysis patients was an LV ejection fraction of less than or equal to 48 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk-stratification studies within the dialysis population are required to better identify those patients at highest risk of SCA and in whom prophylactic interventions may be beneficial.",
"   </p>",
"   <p>",
"    We agree with recommendations concerning evaluation as noted in the 2005 National Kidney Foundation Dialysis Outcome Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/40\">",
"     40",
"    </a>",
"    ]. We recommend that, at initiation of dialysis,",
"    <strong>",
"     all",
"    </strong>",
"    patients should undergo baseline echocardiography and electrocardiography. Echocardiography should be performed after dry weight is attained (which usually occurs after one to three months), and should be repeated routinely at three year intervals. Additional evaluation of left ventricular systolic function should be performed following a change in cardiac status or after an intercurrent cardiac event.",
"   </p>",
"   <p>",
"    Findings of a decreased ejection fraction (less than 40 percent) or significant regional wall motion abnormalities with or without ischemic symptoms requires an evaluation for the presence of coronary artery disease, which may underlie myocardial dysfunction in many dialysis patients.",
"   </p>",
"   <p>",
"    If these surveillance guidelines are met,",
"    <strong>",
"     all",
"    </strong>",
"    dialysis patients with reduced LV function should be identified by echocardiography. Once identified, the main question is whether patients with significantly reduced LV function should be treated with aggressive primary prevention measures, including placement of an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prevention of sudden cardiac arrest in dialysis patients\", section on 'Primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of biomarkers for identification of dialysis patients at high risk for SCD deserves further study. Cardiac troponin T is a strong independent predictor of all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/41\">",
"     41",
"    </a>",
"    ], and high sensitivity CRP is associated with the risk of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11288/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac disease is the major cause of death among dialysis patients. In the United States Renal Data System (USRDS) database, the single largest specific cause of death is attributed to arrhythmic mechanisms or sudden cardiac death (SCD). The overall best current estimate is that SCD is responsible for approximately 27 percent of all-cause mortality in dialysis patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many causes of and risk factors for sudden cardiac arrest (SCA) are shared among patients with and without ESRD, although dialysis patients frequently have a relative increased incidence of abnormalities of the coronary arteries, myocardium, and cardiac conduction system. There are also issues unique to dialysis patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation in the dialysis patient who survives SCA is generally the same as that in the patient without renal failure. However, close attention should be paid to the presence of myocardial dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ischemia, the possibility of improper medication dosing in the patient with renal failure, and the circumstances associated with the event, particularly if it occurred during",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surrounding a hemodialysis session. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"       \"Evaluation of the survivor of sudden cardiac arrest\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid electrolyte shifts during hemodialysis sessions increase the risk of arrhythmias. Variables in the hemodialysis prescription such as the use of low potassium dialysate, low calcium dialysate or large ultrafiltration volumes may be modifiable risk factors for sudden cardiac arrest. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors and causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To help identify the dialysis patient at increased risk of SCA, we recommend that, at initiation of dialysis,",
"      <strong>",
"       all",
"      </strong>",
"      patients should undergo baseline echocardiography and electrocardiography, with echocardiography repeated routinely at three year intervals. Additional evaluation of left ventricular systolic function should be performed following a change in cardiac status or after an intercurrent cardiac event. Findings of a decreased ejection fraction (less than 40 percent) or significant regional wall motion abnormalities (with or without ischemic symptoms) require an evaluation for the presence of coronary artery disease.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     US Renal Data System: USRDS 2011 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/2\">",
"      American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology), Buxton AE, Calkins H, et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). Circulation 2006; 114:2534.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System: USRDS 2006 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006.",
"    </li>",
"    <li>",
"     Herzog, CA. Sudden Cardiac Death in Dialysis Patients. file://www.usrds.org/presentations.htm (Accessed January 4, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/5\">",
"      Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/6\">",
"      Wanner C, Krane V, M&auml;rz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/7\">",
"      Parekh RS, Plantinga LC, Kao WH, et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008; 74:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/8\">",
"      Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2012; 7:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/9\">",
"      Rea TD, Pearce RM, Raghunathan TE, et al. Incidence of out-of-hospital cardiac arrest. Am J Cardiol 2004; 93:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/10\">",
"      Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999; 55:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/11\">",
"      Bleyer AJ, Hartman J, Brannon PC, et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006; 69:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/12\">",
"      Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/13\">",
"      Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997; 336:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/14\">",
"      Shastri S, Tangri N, Tighiouart H, et al. Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol 2012; 7:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/15\">",
"      Herzog, CA, Strief, J, Gilbertson, DT. Cause-specific mortality of dialysis patients after coronary revascularization: Why don't dialysis patients have better survival after coronary intervention? [Abstract]. Circulation Suppl 2004; 110:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/16\">",
"      Herzog CA, Strief JW, Collins AJ, Gilbertson DT. Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention? Nephrol Dial Transplant 2008; 23:2629.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System: USRDS 2002 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/18\">",
"      Pun PH, Lehrich RW, Honeycutt EF, et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011; 79:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/19\">",
"      Young BA. Prevention of sudden cardiac arrest in dialysis patients: can we do more to improve outcomes? Kidney Int 2011; 79:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/20\">",
"      Mangrum, JM, Lin, D, Dimarco, J, et al. Prognostic value of left ventricular systolic function in renal dialysis patients [Abstract]. Heart Rhythm 2006; 3:S154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/21\">",
"      Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/22\">",
"      Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006; 11:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/23\">",
"      Bellomo G, Lippi G, Saronio P, et al. Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study. J Nephrol 2003; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/24\">",
"      Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/25\">",
"      Packer M, Lee WH. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol 1986; 57:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/26\">",
"      Reiter MJ, Mann DE, Williams GR. Interaction of hypokalemia and ventricular dilatation in isolated rabbit hearts. Am J Physiol 1993; 265:H1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/27\">",
"      Halperin BD, Adler SW, Mann DE, Reiter MJ. Mechanical correlates of contraction-excitation feedback during acute ventricular dilatation. Cardiovasc Res 1993; 27:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/28\">",
"      Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol 2010; 21:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/29\">",
"      Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/30\">",
"      Mangrum, AJ, Lin, D, Dimarco, J. Sudden cardiac death and left ventricular function in hemodialysis patients [Abstract]. Heart Rhythm 2006; 2:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/31\">",
"      Yamada S, Ishii H, Takahashi H, et al. Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. Clin J Am Soc Nephrol 2010; 5:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/32\">",
"      Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/33\">",
"      Kruger A, Stewart J, Sahityani R, et al. Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. Kidney Int 2006; 70:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/34\">",
"      Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/35\">",
"      Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/36\">",
"      Mall G, Huther W, Schneider J, et al. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/37\">",
"      Schietinger BJ, Brammer GM, Wang H, et al. Patterns of late gadolinium enhancement in chronic hemodialysis patients. JACC Cardiovasc Imaging 2008; 1:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/38\">",
"      Friedman AN, Groh WJ, Das M. A pilot study in hemodialysis of an electrophysiological tool to measure sudden cardiac death risk. Clin Nephrol 2007; 68:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/39\">",
"      Wang AY, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/40\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11288/abstract/41\">",
"      Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106:2941.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1922 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11288=[""].join("\n");
var outline_f11_1_11288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS AND CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H203921\">",
"      Risk factors related to dialysis prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Survivor of SCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Identification of the high risk dialysis patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1922|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/33/31262\" title=\"figure 1\">",
"      Risk cardiac arrest among HD pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/9/33949\" title=\"figure 2\">",
"      Factors in SCD in dialysis pts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=related_link\">",
"      Treatment and prevention of sudden cardiac arrest in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/59/954?source=related_link\">",
"      Valvular heart disease in patients with end-stage renal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_1_11289="Female pelvic and paraaortic lymph nodes";
var content_f11_1_11289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Female pelvic and paraaortic lymph nodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pelvic and paraaortic lymph nodes and their relationship to the female pelvic organs and the major retroperitoneal blood vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berek JS, Hacker NF. Practical Gynecologic Oncology, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11289=[""].join("\n");
var outline_f11_1_11289=null;
var title_f11_1_11290="Lower urinary tract symptoms in men";
var content_f11_1_11290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lower urinary tract symptoms in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11290/contributors\">",
"     Kevin T McVary, MD-FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11290/contributors\">",
"     Rajiv Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11290/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/1/11290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/1/11290/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/1/11290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"lower urinary tract symptoms,\" or LUTS, is nonspecific. It has been used as a general term to refer to any combination of urinary symptoms or as a more specific term to refer to those symptoms primarily associated with overactive bladder (frequency, urgency, and nocturia). An international consensus conference identified LUTS to include symptoms relating to storage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    voiding disturbances common among aging men [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of lower urinary tract symptoms in men increases with age. LUTS often has a significant negative impact on a patient's quality of life. A survey of over 5000 community-dwelling men age &ge;65 in the US without history of prostate cancer found that 46 percent reported moderate to severe symptoms of LUTS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/2\">",
"     2",
"    </a>",
"    ]. Another community-based study found that the prevalence of LUTS increases steadily with age into the 10th decade, affecting 70 percent of men older than 80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men with LUTS may report one or any combination of the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinary frequency",
"     </li>",
"     <li>",
"      Nocturia",
"     </li>",
"     <li>",
"      Urgency, with or without incontinence",
"     </li>",
"     <li>",
"      Hesitancy in initiating the stream",
"     </li>",
"     <li>",
"      Weak stream",
"     </li>",
"     <li>",
"      Dysuria",
"     </li>",
"     <li>",
"      Sense of incomplete bladder emptying",
"     </li>",
"     <li>",
"      Post void or terminal dribbling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although urinary frequency and urgency suggest an overactive bladder, none of these symptoms are specific or diagnostic for a specific etiology for LUTS.",
"   </p>",
"   <p>",
"    LUTS is also associated with severe sleep disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/4\">",
"     4",
"    </a>",
"    ], increased depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/5\">",
"     5",
"    </a>",
"    ], and decreased ability to perform activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditionally, LUTS in men has been primarily attributed to benign prostatic enlargement (BPE) and consequent bladder outlet obstruction. However, the significance of other etiologies for voiding dysfunction in men is increasingly becoming recognized. Overactive bladder, associated with impairment of detrusor muscle contractility, may be the principal cause or a contributory cause of LUTS symptoms. Careful evaluation is indicated to identify the primary factors responsible for LUTS in an individual patient, in order to target appropriate treatment.",
"   </p>",
"   <p>",
"    This topic will review the clinical presentation, diagnosis, and treatment of lower urinary tract dysfunction in men. A discussion of incontinence is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41737?source=see_link\">",
"     \"Urinary incontinence in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"     \"Treatment of urinary incontinence\"",
"    </a>",
"    .) Additionally, discussion of benign prostatic hyperplasia (BPH) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .) Discussion of nocturia is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=see_link\">",
"     \"Nocturia: Clinical presentation, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CATEGORIZATION OF LUTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LUTS can be categorized as symptoms related to storage, voiding, or post micturition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Storage symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Storage symptoms, experienced during the bladder filling and storage phase of micturition, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urgency &mdash; A sudden compelling desire to pass urine that is difficult to defer.",
"     </li>",
"     <li>",
"      Daytime frequency &mdash; A patient's perception that he voids too often by day.",
"     </li>",
"     <li>",
"      Nocturia &mdash; The need to wake at night one or more times to void.",
"     </li>",
"     <li>",
"      Urge incontinence &mdash; Involuntary leakage, accompanied by, or immediately preceded by, urgency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Voiding symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Voiding symptoms are those experienced at the time of urine flow and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slow stream &mdash; The individual's perception of reduced urine flow, usually compared to previous performance and sometimes compared to observations of other men. Splitting or spraying of the urine stream may be reported.",
"     </li>",
"     <li>",
"      Intermittent stream or intermittency &mdash; Urine flow that stops and starts, on one or more occasions, during micturition.",
"     </li>",
"     <li>",
"      Hesitancy &mdash; Difficulty in initiating micturition, resulting in a delay in the onset of voiding after the individual is ready to pass urine.",
"     </li>",
"     <li>",
"      Straining to void &mdash; An abdominal muscular effort used to initiate, maintain, or improve the urinary stream.",
"     </li>",
"     <li>",
"      Terminal dribble &mdash; Prolongation of the final part of micturition, when the flow has slowed to a",
"      <span class=\"nowrap\">",
"       trickle/dribble",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dysuria &mdash; Pain, burning sensation, or general discomfort at the time of passing urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Post-micturition symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-micturition symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sensation of incomplete emptying after passing urine.",
"     </li>",
"     <li>",
"      Post-micturition dribble &mdash; The involuntary loss of urine shortly following urination, usually after leaving the toilet [",
"      <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BLADDER OUTLET OBSTRUCTION (BOO)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Benign prostatic enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract symptoms in men traditionally have been attributed to an enlarged prostate or benign prostatic enlargement (BPE) as the cause of bladder outlet obstruction (BOO). Benign prostatic hyperplasia (BPH) refers to a specific histologic diagnosis, although the term is commonly used interchangeably with benign prostatic enlargement (BPE), despite the absence of tissue confirmation. We will use BPH here as synonymous with BPE.",
"   </p>",
"   <p>",
"    Clinically significant BPH presents as lower urinary tract symptoms (LUTS) with a predominance of voiding symptoms. Patients experience progressive symptoms that can range from nocturia to acute urinary retention and may include incomplete emptying, urinary hesitancy, weak stream, frequency, and urgency. Long-term or chronic BOO may eventually lead to",
"    <span class=\"nowrap\">",
"     bladder/detrusor",
"    </span>",
"    decompensation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Detrusor overactivity following BOO'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Medical treatment for men with symptomatic BPH includes alpha adrenergic-receptor antagonists (alpha-blockers) and 5-alpha reductase inhibitors, or a combination of these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other causes of BOO",
"    </span>",
"    &nbsp;&mdash;&nbsp;While BPH is the most common cause of BOO in men, it is not the only cause. Other conditions that may cause bladder outlet obstruction include urethral stricture, primary bladder neck obstruction, bladder neck contracture, detrusor-sphincter dyssynergia, and less likely meatal stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OVERACTIVE BLADDER (OAB)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overactive bladder (OAB) is defined by the International Continence Society as a syndrome of urinary urgency, with or without urge incontinence, usually accompanied by increased frequency during both daytime and nighttime nocturia. Although overactive bladder is typically associated with storage symptoms rather than voiding symptoms, OAB often accounts for symptoms in men who are thought to have BOO but who fail to respond to therapy.",
"   </p>",
"   <p>",
"    The incidence of OAB and LUTS symptoms is the same for older adult men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/8\">",
"     8",
"    </a>",
"    ]. Urgency, urge incontinence, and frequency have been reported in 10 to 13 percent of European men 50 to 59 years old and in 18 percent of American men 45 to 54 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The prevalence of OAB rises with increasing age.",
"   </p>",
"   <p>",
"    Typically, the storage symptoms of OAB are more bothersome than the voiding symptoms of BPH. Men with OAB and urge incontinence in particular have higher rates of depression and are more likely to alter activities (eg, decrease work hours, change employment, or take early voluntary retirement) compared to men with OAB who do not have incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OAB symptoms are often attributed to detrusor overactivity (DO), characterized by involuntary detrusor contractions during bladder filling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/12\">",
"     12",
"    </a>",
"    ]. Uninhibited detrusor contractions can be detected on the cystometrogram portion of urodynamic testing.",
"   </p>",
"   <p>",
"    Overactive bladder may be classified as either neurogenic or non-neurogenic. Although the specific mechanism triggering overactivity is essentially unknown, neurogenic OAB symptoms are thought to be related to decreased suprapontine inhibition of the micturition reflex, leading to enhanced excitatory neurotransmission in the micturition reflex pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/13\">",
"     13",
"    </a>",
"    ]. Neurogenic causes include cerebrovascular accident, Parkinson disease, multiple sclerosis, and spinal cord injury. Non-neurogenic, or idiopathic, causes of OAB include BOO (usually secondary to BPH), postoperative pelvic surgery, and bladder stones or other foreign bodies.",
"   </p>",
"   <p>",
"    Current treatment modalities for OAB are directed principally at blocking the muscarinic receptor, the presumed site of neurogenically mediated detrusor overactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OVERLAP OF OAB AND BOO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of OAB overlap with those attributed to BOO secondary to BPH. The incidence of DO with BOO has been reported to range from 30 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/15\">",
"     15",
"    </a>",
"    ]. Because of the similarities and the overlap in symptoms of clinical BPH and OAB, it can be difficult to separate the two conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Detrusor overactivity following BOO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of both BOO and DO in an individual does not confirm causality. Nonetheless, animal models do suggest that BOO can lead to the development of detrusor dysfunction.",
"   </p>",
"   <p>",
"    Tissue ischemia appears to play a central role in BOO-induced detrusor overactivity. Mild bladder distension can cause relative hypoxia in bladder muscle in a canine model, with documentation of reduced detrusor blood flow during filling of hypertrophic bladders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Tissue hypoxemia results from increased oxygen demand by hypertrophic tissue and diminished oxygen supply in the presence of elevated intravesical pressures. Vasodilatory substances, such as nitric oxide synthase, are found in bladder tissue shortly after obstruction and suggest induction of mechanisms to restore blood flow to underperfused areas [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/18\">",
"     18",
"    </a>",
"    ]. It is hypothesized that smooth muscle injury results from a cycle of relative tissue hypoxia during bladder distension, followed by reperfusion injury after micturition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/14,19\">",
"     14,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BOO may also cause DO via cholinergic denervation of the detrusor muscle and consequent supersensitivity of muscarinic receptors to acetylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Animal models suggest that increased bladder outlet resistance may also result in increased detrusor collagen content, changes in electrical properties of detrusor smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/14\">",
"     14",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reorganization of the spinal micturition reflex [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INITIAL PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with symptoms of LUTS, whether to their primary care clinician or to a specialist, should undergo an initial evaluation including history and physical examination. It is important to determine the degree to which symptoms impact the quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/1\">",
"     1",
"    </a>",
"    ]. This assessment can be semiquantitative, but may be facilitated by use of a structured questionnaire. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'International Prostate Symptom Score'",
"    </a>",
"    below.) An algorithm for the initial management of LUTS in men has been developed by an international consortium, representing multiple urological societies from Europe, the United States, Latin America, and Asia (",
"    <a class=\"graphic graphic_algorithm graphicRef57955 \" href=\"UTD.htm?29/60/30657\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    History should include the onset, duration, and severity of symptoms. Medications should be reviewed, as antidepressants, diuretics, bronchodilators, and antihistamines are associated with LUTS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/23\">",
"     23",
"    </a>",
"    ]. Factors associated with urinary incontinence should be clearly ascertained, and patients should be questioned regarding any previous neurologic symptoms, injury or disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41737?source=see_link&amp;anchor=H711968508#H711968508\">",
"     \"Urinary incontinence in men\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination should include evaluation of the abdomen, pelvis, perineum, and a focused neurological exam. A more extensive neurologic examination is indicated for patients with possible neurogenic lower urinary tract dysfunction. An attempt should be made to recreate activities that typically cause incontinence in the patient. Digital rectal exam should be performed to estimate prostate size and detect any abnormalities suggestive of prostate cancer.",
"   </p>",
"   <p>",
"    Initial laboratory studies may include blood tests for renal function and glucose. The benefits and risks of PSA testing should be discussed with the patient. PSA should be considered only in patients with life expectancy greater than ten years. PSA is ordered to screen for prostate cancer and may be used as a proxy for prostate volume in men with LUTS without cancer. Urinalysis and urine culture are performed to evaluate for hematuria and urinary tract infection, respectively. Routine urine cultures are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     International Prostate Symptom Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Prostate Symptom Score (IPSS) is a reproducible, validated index designed to determine disease severity and response to therapy. By itself, it is not a reliable diagnostic tool for LUTS suggestive of BPH, but serves as a quantitative measure of LUTS after the diagnosis is established.",
"   </p>",
"   <p>",
"    The IPSS, similar to the American Urological Association's Symptom Score (AUASS), consists of seven questions related to voiding symptoms (",
"    <a class=\"graphic graphic_table graphicRef57680 \" href=\"UTD.htm?21/50/22317\">",
"     table 1",
"    </a>",
"    ). Scores of 0 to 7, 8 to 19, and 20 to 35 signify mild, moderate, and severe symptoms, respectively.",
"   </p>",
"   <p>",
"    In addition, the IPSS includes a quality of life score as a single 7-point scale question asking the patient how he would feel if he were to spend the rest of his life with his current urinary condition. Similarly, the International Consultation on Incontinence Modular Questionnaire - Male LUTS (ICIQ-MLUTS) asks patients to rate, on a scale of 0 to 10, how much leaking urine interferes with everyday life [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indications for specialist referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is reasonable to initiate a trial of therapy for BPH when the primary care clinician is comfortable that presenting signs and symptoms are consistent with BOO due to BPH as the probable source of LUTS.",
"   </p>",
"   <p>",
"    Men who predominantly have storage symptoms, suggesting OAB, should be evaluated for postvoid residual (PVR) before anticholinergic medication is initiated. A referral to urology should be considered if the PVR cannot be determined in the primary care setting, or if the patient has not responded to a trial of medication for BPH.",
"   </p>",
"   <p>",
"    Referral to a urological specialist may also be appropriate for patients with LUTS and any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Men &lt;45 years old",
"     </li>",
"     <li>",
"      Abnormality on prostate examination",
"     </li>",
"     <li>",
"      Presence of hematuria in the absence of infection",
"     </li>",
"     <li>",
"      Failure to respond to initial treatment for LUTS",
"     </li>",
"     <li>",
"      Men who desire surgical treatment",
"     </li>",
"     <li>",
"      Men with incontinence",
"     </li>",
"     <li>",
"      Men with severe symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy regarding the role of diagnostic studies in the evaluation of men with LUTS who are referred to a urologist. Guidelines from the American Urological Association (AUA) advise that all testing (including uroflowmetry, PVR, pressure-flow urodynamics, and cystoscopy) be considered optional [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/25\">",
"     25",
"    </a>",
"    ]. The 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases recommends urine flow rate measurement (Qmax) and PVR, measured by ultrasonography, prior to initiating active treatment, and for subsequent monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/1\">",
"     1",
"    </a>",
"    ]. Pressure-flow studies are recommended for the evaluation of patients before invasive therapies (when Qmax is greater than 10 mL per second) or when a precise diagnosis of BOO is important. Both panels suggest cystoscopy and imaging of the prostate and upper tracts when indicated for evaluation of possible renal or malignant disease (eg, recurrent urinary infection, hematuria, renal insufficiency).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Noninvasive studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive studies for LUTS include uroflowmetry to measure maximum urinary flow rate (Qmax), bladder scan or ultrasound to determine postvoid residual urine volume (PVR), or transabdominal ultrasound to assess bladder anatomy for evidence of outlet obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Uroflowmetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uroflowmetry is a simple non-invasive urodynamic measurement in which a patient urinates into a device that measures the",
"    <span class=\"nowrap\">",
"     volume/time",
"    </span>",
"    of urine accumulation. Combined with a measurement of postvoid residual volume (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Postvoid residual'",
"    </a>",
"    below), it is an excellent screening tool for BOO in men with LUTS, but does not provide information regarding the presence of OAB. Additionally, a diagnosis of BOO cannot be made or excluded based on uroflowmetry alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uroflowmetry measures voided volume, voiding time, average flow rate, and maximum flow rate (Qmax). It also provides a linear analysis of the flow",
"    <span class=\"nowrap\">",
"     rate/voiding",
"    </span>",
"    time so that the voiding pattern can be evaluated (",
"    <a class=\"graphic graphic_figure graphicRef79658 \" href=\"UTD.htm?23/18/23855\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Qmax is the single best measurement obtained by this study to assess voiding dysfunction. However, a low Qmax does not distinguish between obstruction (BOO) and decreased detrusor contractility, and a normal Qmax does not exclude BOO. Qmax may be normal in the early stages of obstruction, due to compensatory increase in detrusor contractility resulting in high voiding pressures.",
"   </p>",
"   <p>",
"    Approximately 85 to 90 percent of men with a Qmax less than 10",
"    <span class=\"nowrap\">",
"     mL/s",
"    </span>",
"    are found to be obstructed on pressure-flow studies. BOO can be accurately diagnosed in men with a Qmax of less than 10",
"    <span class=\"nowrap\">",
"     mL/s",
"    </span>",
"    and an IPSS greater than 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to Qmax, the flow pattern should be noted; characteristic patterns may have diagnostic relevance. Obstruction generally demonstrates a flattened flow pattern with a low Qmax, a prolonged flow time, and a slow time to maximum flow (",
"    <a class=\"graphic graphic_figure graphicRef58694 \" href=\"UTD.htm?16/10/16544\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Postvoid residual",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most urologists perform a postvoid residual (PVR) as part of their assessment, PVR does not correlate with the severity of LUTS, the presence of BOO, or treatment outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/28\">",
"     28",
"    </a>",
"    ]. An elevated PVR is found with obstruction, but may also indicate detrusor decompensation due to various causes, including chronic BOO. PVR does not provide diagnostic information for OAB.",
"   </p>",
"   <p>",
"    Measurements from uroflowmetry, and sometimes pressure-flow urodynamics, are necessary to determine the etiology of an elevated PVR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, a man with a low Qmax and a high PVR may have either BOO or detrusor decompensation. Urodynamic studies could determine if the etiology of the elevated PVR were due to BOO, requiring treatment with alpha-blockers or surgery, or to detrusor compensation which might require catheter drainage or close surveillance.",
"   </p>",
"   <p>",
"    An elevated PVR in some patients may have a secondary effect on the upper tracts. The presence of hydronephrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal insufficiency could be evaluated with a renal ultrasound and serum creatinine. Although evidence-based cutoffs do not exist, we believe that upper tract imaging should be considered in men with postvoid residuals greater than 200 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4254115\">",
"    <span class=\"h3\">",
"     Transabdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal ultrasound can be used to assess bladder wall thickness, detrusor wall thickness, and bladder weight. Although there is no established cut-off value, increased detrusor wall thickness is associated with urodynamically-confirmed bladder outlet obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Invasive diagnostic studies",
"    </span>",
"   </p>",
"   <p>",
"    More invasive studies include pressure-flow urodynamic studies, cystoscopy, and measurement of prostate volume by transrectal ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pressure-flow studies and urodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urodynamic studies are the gold standard for diagnosis of uninhibited detrusor contractions that occur during the filling phase of voiding in OAB [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/30\">",
"     30",
"    </a>",
"    ]. Urodynamics are important in the evaluation of male patients with neurological disease, and in patients who fail treatment for BOO. Urodynamics are often performed before empiric treatment, when a non-BOO etiology is suspected, or when invasive treatment is contemplated. Additionally, men under age 50 should be evaluated with urodynamic studies prior to treatment due to the high incidence of non-obstructive etiology for LUTS in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urodynamic evaluation involves the concurrent multi-channel measurement of bladder and abdominal pressures during the",
"    <span class=\"nowrap\">",
"     filling/storage",
"    </span>",
"    and voiding phase of micturition. Detrusor pressure is calculated as the difference between the bladder and abdominal pressures. Urodynamics are the best method to diagnose high-pressure, low-flow voiding that is typical of BOO, and differentiate it from low or normal pressure low-flow voiding due to detrusor decompensation.",
"   </p>",
"   <p>",
"    Several parameters are measured to assess the relationship between flow and pressure during micturition. These include the Abrams-Griffiths nomogram and the more commonly used BOO index (BOOI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The BOOI relates the detrusor pressure at maximum flow (Pdet) to Qmax; an elevated BOOI indicates obstruction.",
"   </p>",
"   <p>",
"    The cystometrogram provides information regarding bladder storage capacity, bladder sensation, the presence or absence of DO, and bladder compliance (the ability of the bladder to expand and accommodate increasing volumes of urine). The role of the cystometrogram to evaluate the bladder as a source of male LUTS is often overlooked, because of a focus on the prostate as the sole cause of symptoms.",
"   </p>",
"   <p>",
"    Storage LUTS symptoms in men may result from detrusor overactivity, obstruction, or other bladder abnormalities. The cystometrogram may demonstrate a normal pattern, or some combination of the following abnormalities during filling: reduced maximum cystometric capacity (&lt;150 mL), involuntary detrusor contractions (&gt;10 cm H20), or loss of bladder compliance. A man with urge incontinence may demonstrate high-pressure involuntary detrusor contractions, low bladder capacity, and poor reflex contraction of the urethral sphincter mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/26,34\">",
"     26,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors may influence the constellation of symptoms for any individual patient and must be taken into account in developing an appropriate treatment regimen. Based on the initial evaluation, patients may be found to have BOO, OAB, or both. Algorithms for initial treatment of LUTS and for treatment of persistent bothersome LUTS have been developed by an international consortium, representing multiple urological societies from Europe, the United States, Latin America, and Asia (",
"    <a class=\"graphic graphic_algorithm graphicRef57955 \" href=\"UTD.htm?29/60/30657\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef60795 \" href=\"UTD.htm?22/47/23282\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavioral modifications may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/35\">",
"     35",
"    </a>",
"    ], particularly as an adjunct to medication. Lifestyle changes include avoiding fluids prior to bedtime or before going out and reducing consumption of mild diuretics such as caffeine and alcohol. Training in biofeedback to promote pelvic relaxation may be particularly helpful for patients with urgency symptoms. A randomized trial found that men with LUTS who were given an intervention that included education, lifestyle advice, and problem solving skills were significantly less likely to experience treatment failure (increase in IPSS or requirement for medication) compared with the control group (watchful waiting) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial treatment for BOO secondary to BPH is generally pharmacologic, especially in patients with mild-to-moderate symptoms and no clear indication for surgical intervention. Current medical therapy consists of alpha-blockers, 5-alpha reductase inhibitors, or a combination of these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical treatment is usually reserved for medication failure, progressive symptoms, or patient preference. Surgical options include minimally invasive surgical therapies (microwave therapy, transurethral radiofrequency ablation), laser vaporization of prostate, transurethral resection of prostate, and open prostatectomy. An extensive discussion of surgical treatment options for BOO related to BPH is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alpha adrenergic-receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-blockers are first-line agents used for the treatment of symptomatic BPH. They function to relax the smooth muscle tone at the bladder neck and prostate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link&amp;anchor=H5#H5\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on 'Alpha-1-adrenergic antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, five agents are approved:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17653?source=see_link\">",
"     silodosin",
"    </a>",
"    . Non-selective alpha-blockers (terazosin, doxazosin) require dose titration and are associated with dizziness and hypotension, a particular problem in an elderly population. The more selective alpha-blockers (tamsulosin and silodosin) specifically target the bladder neck and prostate, and have fewer adverse cardiovascular side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     5-alpha reductase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-alpha reductase inhibitors competitively block the enzyme 5-alpha reductase, and inhibit the conversion of testosterone to dihydrotestosterone. This results in epithelial atrophy and reduction of prostate volume up to 25 percent over time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. These agents are useful for LUTS secondary to BPH only in the presence of prostate enlargement (documented by digital rectal examination, PSA for volume proxy, or transrectal ultrasound). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link&amp;anchor=H10#H10\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on '5-alpha-reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two agents are available in the US:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    . Long-term placebo-controlled studies of both agents show significant improvements in IPSS and Qmax after a minimum of three months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Both finasteride and dutasteride, compared to placebo, decrease the risk of acute urinary retention and need for BPH-related surgery. Significant adverse events included ejaculatory disorder, erectile dysfunction, decreased libido, and gynecomastia. Only gynecomastia remained at a rate higher than placebo after one year of use.",
"   </p>",
"   <p>",
"    In randomized trials, 5-alpha-reductase inhibitors significantly decrease the incidence of prostate cancer. However, concern has been raised about whether 5-alpha-reductase inhibitors increase the incidence of high-grade lesions, although many believe this finding is spurious. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemoprevention strategies in prostate cancer\", section on '5-Alpha reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) recommends that, before starting 5-alpha reductase inhibitors for treatment of BPH, the patient should be assessed for other urological conditions, including prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/39\">",
"     39",
"    </a>",
"    ]. This advisory from the FDA emphasizes the need to monitor these patients for prostate cancer and to recognize the effect that these drugs have on PSA levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with both alpha blocker and alpha reductase inhibitor drugs has been evaluated in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. A randomized trial sponsored by the National Institutes of Health found that combination therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ), compared with placebo or monotherapy with either drug, showed greater improvement in IPSS score and Qmax after four years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/44\">",
"     44",
"    </a>",
"    ]. The greatest reduction in rates of acute urinary retention and the need for BPH-related surgery were in the finasteride-only and combination groups. The multicenter randomized CombAT study also found that combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    was more effective than monotherapy with either drug alone for long-term symptom improvement (IPSS score) in men with moderate to severe LUTS related to BPH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with LUTS related to OAB, the primary goal is to decrease involuntary detrusor contractions. Normal bladder contractions are primarily triggered by the neurotransmitter acetylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies of anticholinergic agents evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , an acetylcholine muscarinic receptor antagonist. Atropine increases the bladder volume before the first involuntary contraction, increases maximum bladder capacity, and decreases the amplitude of the contraction. Clinically, atropine decreases episodes of urge incontinence and the frequency of urgency episodes, but is most effective when combined with behavioral modification [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The human bladder has five cholinergic muscarinic receptor subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The M2 and M3 types are found on detrusor muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/50\">",
"     50",
"    </a>",
"    ]. Most smooth muscle contractions are mediated via the M3 type. The M2 type contributes to bladder contraction in certain disease states (eg, outflow obstruction and denervation) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"     Tolterodine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43733?source=see_link\">",
"     darifenacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/33/39445?source=see_link\">",
"     solifenacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/53/28501?source=see_link\">",
"     fesoterodine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/9/26773?source=see_link\">",
"     trospium",
"    </a>",
"    are currently approved in the US for OAB, and in placebo-controlled trials have been shown to reduce the sensation of urgency, decrease episodes of frequency and urge incontinence, and increase voided volume [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. A 2006 systematic review found that, compared to placebo, anticholinergic drugs for OAB were more likely to cure or improve symptoms (RR 1.4, 95% CI 1.3-1.5), decrease urinary leakage (weighted mean difference [WMD] -0.54, -0.67 to -0.41), and decrease the number of voids in 24 hours (WMD 0.69, -0.84 to -0.54) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant peripheral side effects, attributed to M2 blockade, limit drug tolerability and dose escalation. Side effects include inhibition of salivary secretion (dry mouth), blockade of the ciliary muscle of the lens to cholinergic stimulation (blurred vision for near objects), tachycardia, drowsiness, decreased cognitive function, and inhibition of gut motility and constipation. Antimuscarinic agents are contraindicated in patients with gastric retention and angle closure glaucoma.",
"   </p>",
"   <p>",
"    The anticholinergic tertiary amines, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43733?source=see_link\">",
"     darifenacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/33/39445?source=see_link\">",
"     solifenacin",
"    </a>",
"    , are selective M3 receptor antagonist. Selective M3 blockade theoretically may decrease peripheral side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/9/26773?source=see_link\">",
"     Trospium",
"    </a>",
"    is a quaternary amine, and is classified as a smooth muscle relaxant with some anticholinergic effects. It has limited ability to cross the blood-brain barrier, and may have less impact on cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 86 randomized trials and meta-analysis of 70 trials in patients with overactive bladder symptoms compared differing doses and formulations of four anticholinergic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/60\">",
"     60",
"    </a>",
"    ]. Findings were that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    was better tolerated than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    and that extended-release formulations of these agents were better tolerated than immediate release.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/53/28501?source=see_link\">",
"     Fesoterodine",
"    </a>",
"    had better efficacy than extended-release tolterodine but caused more dry mouth leading to drug withdrawal.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/33/39445?source=see_link\">",
"     Solifenacin",
"    </a>",
"    was more effective and better tolerated than immediate-release tolterodine. Data were not available for other comparisons. There were incomplete data to make conclusions about comparative costs, long-term outcomes, or the impact on quality of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of urinary incontinence\", section on 'Antimuscarinics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of anticholinergics in men with OAB has traditionally been considered contraindicated due to concerns about precipitating urinary retention. However, most placebo-controlled studies have demonstrated safety and efficacy of anticholinergic medications in patients with OAB, with or without BOO.",
"   </p>",
"   <p>",
"    In the 2011 AUA BPH Clinical Guidelines, anticholinergic agents were considered effective treatment alternatives for the management of LUTS secondary to BPH in men without an elevated post void residual (PVR) urine and when LUTS are predominantly irritative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/25\">",
"     25",
"    </a>",
"    ]. The panel recommended that prior to initiation of anticholinergic therapy, baseline PVR urine should be assessed. Anticholinergics should be used with caution in patients with a PVR greater than 250 to 300 mL. Randomized trials evaluating the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    as monotherapy or in combination with an alpha blocker in men with",
"    <span class=\"nowrap\">",
"     OAB/LUTS/BPH",
"    </span>",
"    were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/12,61,62\">",
"     12,61,62",
"    </a>",
"    ]. Although these trials did not consistently demonstrate efficacy of tolterodine, the AUA Panel concluded that the use of anticholinergics could be beneficial.",
"   </p>",
"   <p>",
"    In summary, there are insufficient data on the use of antimuscarinic agents for the treatment of BPH related LUTS either as monotherapy or in combination with other medical therapy. The limited spectrum of medications studied as well the intrinsic flaws of study designs (ie, branded medicines versus older generics) results in this weak endorsement for the use of this class of agents for therapy. However, these limited data do suggest that the use of anticholinergic agents in men with LUTS may be a safe and potentially-effective alternative to traditional therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Phosphodiesterase 5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that men with erectile dysfunction treated with phosphodiesterase (PDE) 5 inhibitors reported a decrease in LUTS led to several clinical trials. These trials have demonstrated marked improvement in LUTS among men with benign prostatic hyperplasia taking PDE 5 inhibitors compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/63\">",
"     63",
"    </a>",
"    ]. These trials have used symptom summary scores as outcomes, and not specifically reported impact on incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link&amp;anchor=H21#H21\">",
"     \"Medical treatment of benign prostatic hyperplasia\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment for urodynamically-proven OAB",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     No obstruction and low PVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergics can be used safely and effectively in this group of patients with non-neurogenic OAB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     No obstruction and high PVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a limited role for outlet reduction surgery in the absence of clear evidence for BOO. Patients with elevated PVR and no obstruction are described to have detrusor hyperactivity with impaired contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cautious trial of anticholinergic therapy may be initiated, with close attention to the PVR. If the PVR remains high, patients may need additional measures to empty their bladder, including intermittent catheterization.",
"   </p>",
"   <p>",
"    A large PVR may be well tolerated, as long as bladder compliance is normal and the patient does not become prone to urinary tract infections. Some patients may be treated with a combination of outlet reduction surgery, biofeedback (to teach pelvic floor relaxation techniques), and Valsalva or Crede voiding to empty the bladder. In this subset of patients (equivocal bladder outlet obstruction), removing even a minor obstruction may aid in emptying the bladder when combined with other interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/65\">",
"     65",
"    </a>",
"    ]. Valsalva voiding involves tightening the lower abdominal muscles so that pressure is transmitted to the bladder to help in emptying; Crede voiding is the application of direct pressure (fist or hand) over the lower abdomen or suprapubic area to transmit pressure to the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     BOO with low PVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is the most common combination of findings in clinical practice. These men are often started on alpha-blockers, which, in addition to relieving obstruction by relaxing prostatic smooth muscle, may also improve symptoms of OAB. On urodynamic testing, patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    monotherapy showed an increase in the volume at first involuntary contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/62\">",
"     62",
"    </a>",
"    ]. Anticholinergics can be added if OAB symptoms persist.",
"   </p>",
"   <p>",
"    Surgical reduction of BOO is an acceptable treatment alternative. As previously discussed, up to 60 percent of men with BOO have evidence of DO. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Overlap of OAB and BOO'",
"    </a>",
"    above.) BOO reduction surgery results in resolution of DO in one half of men with DO preoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/66\">",
"     66",
"    </a>",
"    ]. Importantly, relieving the obstruction may prevent worsening of OAB [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men with DO and BOO may have postoperative urinary urgency and incontinence. Unlike postoperative stress urinary incontinence (resulting from injury to the continence mechanism during resection), this urgency may be due to long-standing BPH, urinary tract infection (UTI),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postoperative irritability of the prostatic fossa. Symptoms may continue until the UTI is treated or the prostatic fossa heals. In most cases, conservative treatment is recommended. Urodynamics can be helpful for persistent urge symptoms to distinguish detrusor overactivity from other causes of irritative symptoms. Anticholinergic medication, combined with anti-inflammatory therapy, usually provide effective treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     BOO with high PVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with evidence of obstruction and elevated PVR should initially be treated for relief of their obstruction by either medical or surgical therapy. This group is at high risk of urinary retention with anticholinergic therapy, and therapy for OAB symptoms should be delayed until obstruction is relieved.",
"   </p>",
"   <p>",
"    If symptoms persist after medical treatment or surgery, patients should be re-evaluated with urodynamic studies, including the determination of PVR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/65\">",
"     65",
"    </a>",
"    ]. A subset of these patients will have OAB with detrusor decompensation. It is important to closely monitor those patients, as they are at the highest risk of developing urinary retention with anticholinergic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Refractory OAB",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Pelvic neuromodulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with OAB symptoms refractory to medical therapy may be candidates for pelvic neuromodulation. Sacral neuromodulation involves the electrical stimulation of S3 and S4 nerve roots via electrodes implanted adjacent to the S3 dorsal roots. A pacemaker-like stimulator is placed under the skin of a buttock. The exact mechanism of action is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of urinary incontinence\", section on 'Electrical'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most clinical studies of these devices have focused on women with urgency urinary incontinence. The common innervation of the bladder makes it likely that clinical outcomes would be similar for men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin causes muscle relaxation through inhibition of acetylcholine release. Cystoscopic injection of botulinum toxin directly into the detrusor muscle results in chemical denervation that is reversible after 6 to 9 months. Type A serotype is used in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Botulinum toxin is not FDA-approved for use in OAB, although multiple case reports show safety and efficacy with off-label use in patients with neurogenic causes of DO (eg, spinal cord injury and multiple sclerosis). Botulinum toxin A has also been used in patients with non-neurogenic DO and OAB, but is typically reserved for patients with symptoms refractory to anticholinergic agents.",
"   </p>",
"   <p>",
"    A 2007 systematic review of randomized trials of botulinum, compared to no treatment, non-pharmacologic, and pharmacologic treatment for overactive bladder, found few well controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/1/11290/abstract/69\">",
"     69",
"    </a>",
"    ]. Eight small trials, including patients of mixed gender with predominantly neurogenic OAB, demonstrated superiority of botulinum to placebo in episodes of incontinence, bladder capacity and quality of life. The review concluded that intravesical botulinum shows promise, but there is no robust data regarding safety or optimal dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/21/15698?source=see_link\">",
"       \"Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=see_link\">",
"       \"Patient information: Neurogenic bladder in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=see_link\">",
"       \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"       \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"       \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower urinary tract symptoms (LUTS) can be classified as storage symptoms (urgency, frequency, nocturia, urge incontinence), voiding symptoms (hesitancy, weak stream, dysuria), or post-micturition symptoms (incomplete bladder emptying, post-micturition dribbling). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Categorization of LUTS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LUTS in men has most often been attributed to bladder outlet obstruction (BOO) resulting from prostatic enlargement or benign prostatic hyperplasia (BPH). Voiding symptoms are suggestive of BOO, but are not diagnostic. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bladder outlet obstruction (BOO)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overactive bladder (OAB) is related to detrusor overactivity and is most commonly associated with storage symptoms that are frequently more bothersome than voiding symptoms. The cause of OAB is often unknown. OAB may be neurogenic (ie, secondary to stroke or other neurologic condition) or may be caused by chronic obstruction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overactive bladder (OAB)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Male patients with LUTS should be evaluated initially with history, physical examination, and laboratory studies, which may include creatinine, glucose, PSA, urinalysis, and urine culture. Determining the International Prostate Symptom Score (IPSS) can be helpful in monitoring treatment response. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant symptoms and findings consistent with BPH and BOO as cause for LUTS may be treated empirically. We suggest urological referral for men who are less than 45 years old or who do not respond to empiric therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"       \"Medical treatment of benign prostatic hyperplasia\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H14\">",
"       'Indications for specialist referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role for urological studies in evaluating LUTS is controversial. Postvoid residual does not correlate with LUTS severity or provide diagnostic information regarding BOO or OAB. However, awareness of an elevated PVR may guide treatment with anticholinergic medication. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical treatment for BPH and BOO includes alpha blockers, 5-alpha reductase inhibitors, or a combination. Surgical treatment is usually reserved for medication failure, progressive symptoms, or patient preference. Relief of obstruction may not relieve symptoms related to OAB, and urodynamic studies may be helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"       \"Medical treatment of benign prostatic hyperplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"       \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical options include minimally-invasive surgical therapies (microwave therapy, transurethral radiofrequency ablation), laser vaporization of prostate, transurethral resection of prostate, and open prostatectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"       \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticholinergic medications are used for OAB treatment, but can cause orthostasis, dry mouth, blurred vision, and urinary retention. We suggest that men with urgency symptoms and no evidence of a significantly-elevated PVR be treated with an anticholinergic medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Side effects may be minimized by using a low dose of medication, long-acting preparations, and by using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"       tolterodine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Anticholinergics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that men with symptoms of OAB and BOO be treated with combination therapy (an anticholinergic plus an alpha blocker) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Caution should be taken to observe for symptoms suggesting urinary retention. We recommend that men who have a significantly-elevated PVR not be treated with an anticholinergic medication until obstruction is relieved, either medically or surgically (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/1\">",
"      Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009; 181:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/2\">",
"      Taylor BC, Wilt TJ, Fink HA, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006; 68:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/3\">",
"      Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged &gt; or = 80 years. Urology 2008; 72:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/4\">",
"      Helfand BT, McVary KT, Meleth S, et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. J Urol 2011; 185:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/5\">",
"      Laumann EO, Kang JH, Glasser DB, et al. Lower urinary tract symptoms are associated with depressive symptoms in white, black and Hispanic men in the United States. J Urol 2008; 180:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/6\">",
"      Jones C, Hill J, Chapple C, Guideline Development Group. Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ 2010; 340:c2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/7\">",
"      Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/8\">",
"      Schatzl G, Temml C, Waldm&uuml;ller J, et al. A comparative cross-sectional study of lower urinary tract symptoms in both sexes. Eur Urol 2001; 40:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/9\">",
"      Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/10\">",
"      Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/11\">",
"      Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006; 97:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/12\">",
"      Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/13\">",
"      de Groat WC. A neurologic basis for the overactive bladder. Urology 1997; 50:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/14\">",
"      Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002; 3:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/15\">",
"      Lee JY, Kim DK, Chancellor MB. When to use antimuscarinics in men who have lower urinary tract symptoms. Urol Clin North Am 2006; 33:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/16\">",
"      Finkbeiner A, Lapides J. Effect of distension on blood flow in dog's urinary bladder. Invest Urol 1974; 12:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/17\">",
"      Lin AT, Chen MT, Yang CH, Chang LS. Blood flow of the urinary bladder: effects of outlet obstruction and correlation with bioenergetic metabolism. Neurourol Urodyn 1995; 14:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/18\">",
"      Lemack GE, Burkhard F, Zimmern PE, et al. Physiologic sequelae of partial infravesical obstruction in the mouse: role of inducible nitric oxide synthase. J Urol 1999; 161:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/19\">",
"      Uvelius B, Arner A. Changed metabolism of detrusor muscle cells from obstructed rat urinary bladder. Scand J Urol Nephrol Suppl 1997; 184:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/20\">",
"      Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/21\">",
"      Speakman MJ, Brading AF, Gilpin CJ, et al. Bladder outflow obstruction--a cause of denervation supersensitivity. J Urol 1987; 138:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/22\">",
"      Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 2002; 4 Suppl 4:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/23\">",
"      Wuerstle MC, Van Den Eeden SK, Poon KT, et al. Contribution of common medications to lower urinary tract symptoms in men. Arch Intern Med 2011; 171:1680.",
"     </a>",
"    </li>",
"    <li>",
"     International Consultation on Incontinence Modular Questionaire (ICIQ). Available at: www.iciq.net/ICIQ.MLUTS.html (Accessed on April 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/25\">",
"      McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/26\">",
"      MacDiarmid S, Rogers A. Male overactive bladder: the role of urodynamics and anticholinergics. Curr Urol Rep 2007; 8:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/27\">",
"      Porru D, Jallous H, Cavalli V, et al. Prognostic value of a combination of IPSS, flow rate and residual urine volume compared to pressure-flow studies in the preoperative evaluation of symptomatic BPH. Eur Urol 2002; 41:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/28\">",
"      AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/29\">",
"      Bright E, Oelke M, Tubaro A, Abrams P. Ultrasound estimated bladder weight and measurement of bladder wall thickness--useful noninvasive methods for assessing the lower urinary tract? J Urol 2010; 184:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/30\">",
"      Dmochowski RR. Bladder outlet obstruction: etiology and evaluation. Rev Urol 2005; 7 Suppl 6:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/31\">",
"      Kaplan SA, Ikeguchi EF, Santarosa RP, et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996; 47:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/32\">",
"      Lim CS, Abrams P. The Abrams-Griffiths nomogram. World J Urol 1995; 13:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/33\">",
"      Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 1999; 84:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/34\">",
"      Dmochowski R. Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep 2006; 7:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/35\">",
"      Burgio KL, Goode PS, Johnson TM, et al. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc 2011; 59:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/36\">",
"      Brown CT, Yap T, Cromwell DA, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007; 334:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/37\">",
"      Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/38\">",
"      Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258529.htm (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/40\">",
"      Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/41\">",
"      Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/42\">",
"      Sandhu JS, Vaughan ED Jr. Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options. Drugs Aging 2005; 22:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/43\">",
"      MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/44\">",
"      McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/45\">",
"      Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/46\">",
"      Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/47\">",
"      McGuire, EJ, Savastano, JA. Effect of alpha adrenergic blockade and anticholinergic agents on the decentralized primate bladder. Neurourol Urodyn 1985; 4:139.",
"     </a>",
"    </li>",
"    <li>",
"     Andersson KE, Wein AJ. Pharmacologic Management of Storage and Emptying Failure. In: Campbell-Walsh Urology, 9th ed, Wein AJ, Kavoussi LR, Novick AC, et al (Eds), Saunders Elsevier, Philadelphia 2007. p.2091.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/49\">",
"      Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989; 12:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/50\">",
"      Levin RM, Ruggieri MR, Wein AJ. Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. J Urol 1988; 139:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/51\">",
"      Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/52\">",
"      Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/53\">",
"      Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/54\">",
"      Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/55\">",
"      Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999; 39:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/56\">",
"      MacDiarmid SA, Ellsworth PI, Ginsberg DA, et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology 2011; 77:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/57\">",
"      Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; :CD003781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/58\">",
"      Staskin D, Sand P, Zinner N, et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007; 178:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/59\">",
"      Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am 2006; 33:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/60\">",
"      Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012; 1:CD005429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/61\">",
"      Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/62\">",
"      Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/63\">",
"      Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology 2011; 77:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/64\">",
"      Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA 1987; 257:3076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/65\">",
"      Ng CK, Gonzalez RR, Te AE. Refractory overactive bladder in men: update on novel therapies. Curr Urol Rep 2006; 7:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/66\">",
"      Van Venrooij GE, Van Melick HH, Eckhardt MD, Boon TA. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002; 168:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/67\">",
"      Leng WW, Davies BJ, Tarin T, et al. Delayed treatment of bladder outlet obstruction after sling surgery: association with irreversible bladder dysfunction. J Urol 2004; 172:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/68\">",
"      Cohen BL, Rivera R, Barboglio P, Gousse A. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol 2007; 177:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/1/11290/abstract/69\">",
"      Duthie J, Wilson DI, Herbison GP, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2007; :CD005493.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6879 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11290=[""].join("\n");
var outline_f11_1_11290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CATEGORIZATION OF LUTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Storage symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Voiding symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Post-micturition symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BLADDER OUTLET OBSTRUCTION (BOO)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Benign prostatic enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other causes of BOO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OVERACTIVE BLADDER (OAB)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OVERLAP OF OAB AND BOO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Detrusor overactivity following BOO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INITIAL PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      International Prostate Symptom Score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indications for specialist referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Noninvasive studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Uroflowmetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Postvoid residual",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4254115\">",
"      - Transabdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Invasive diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pressure-flow studies and urodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alpha adrenergic-receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      5-alpha reductase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Phosphodiesterase 5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment for urodynamically-proven OAB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - No obstruction and low PVR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - No obstruction and high PVR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - BOO with low PVR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - BOO with high PVR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Refractory OAB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Pelvic neuromodulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6879\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6879|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/60/30657\" title=\"algorithm 1\">",
"      Basic management LUTS men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/47/23282\" title=\"algorithm 2\">",
"      Special management LUTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6879|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/18/23855\" title=\"figure 1\">",
"      Uroflowmetry normal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/10/16544\" title=\"figure 2\">",
"      Male obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6879|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/50/22317\" title=\"table 1\">",
"      International Prostate Symptom Score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=related_link\">",
"      Nocturia: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/21/15698?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=related_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=related_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=related_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41737?source=related_link\">",
"      Urinary incontinence in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_1_11291="Clinical findings OHSS";
var content_f11_1_11291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings in women with ovarian hyperstimulation syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" style=\"width: 643px; height: 75px;\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Bloating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea, vomiting, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lethargy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shortness of breath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oliguria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid weight gain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoconcentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyponatremia, hyperkalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural and pericardial effusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercoagulability and thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult respiratory distress syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11291=[""].join("\n");
var outline_f11_1_11291=null;
var title_f11_1_11292="Maneuvers mitral valve prolapse";
var content_f11_1_11292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alterations in S1-click interval and the character of the late systolic murmur during physiologic and pharmacologic maneuvers in mitral valve prolapse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Maneuvers",
"       </td>",
"       <td class=\"subtitle1\">",
"        S1-click interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset of late systolic murmur in relation to S1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of late systolic murmur in relation to total duration of systole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supine position",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Late",
"       </td>",
"       <td>",
"        Shorter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Standing position",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Early",
"       </td>",
"       <td>",
"        Longer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squatting*",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Late",
"       </td>",
"       <td>",
"        Shorter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valsalva (phase 2)",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Early",
"       </td>",
"       <td>",
"        Longer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hand grip",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Late",
"       </td>",
"       <td>",
"        Shorter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postectopic beat",
"       </td>",
"       <td>",
"        Usually decreased",
"       </td>",
"       <td>",
"        Usually late",
"       </td>",
"       <td>",
"        Usually longer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyl nitrite",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Early",
"       </td>",
"       <td>",
"        Longer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylephrine",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Late",
"       </td>",
"       <td>",
"        Shorter",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The delay in the onset of the click and a shortening of the late systolic murmur with squatting reflects a delay in prolapse induced by the increase in preload; the reverse changes occur with standing. However, as mitral regurgitation becomes more severe, the murmur may increase in intensity with squatting because of the increase in afterload.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11292=[""].join("\n");
var outline_f11_1_11292=null;
var title_f11_1_11293="Signs DDH";
var content_f11_1_11293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings in infants and children with developmental dysplasia of the hip",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Birth to 3 months of age",
"       </td>",
"       <td class=\"subtitle1_single centered\">",
"        Unilateral",
"        <br/>",
"        (80 percent of cases)",
"       </td>",
"       <td class=\"subtitle1_single centered\">",
"        Bilateral",
"        <br/>",
"        (20 percent of cases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hip instability (demonstrated by positive Ortolani or Barlow tests)*",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymmetric leg creases (inguinal, gluteal, thigh, or popliteal)",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         No",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apparent shortening of femur (Galeazzi, Allis, or Perkins sign)",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         No",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3 to 12 months of age",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limitation of hip abduction in 90&deg; of flexion",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apparent shortening of the femur (Galeazzi, Allis, or Perkins sign)",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         No",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laterally rotated posture in prone position (ie, increased femoral anteversion)",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked asymmetry of leg creases (inguinal, gluteal, thigh, or popliteal)",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         No",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Klisic test",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        After the child begins to walk",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive lordosis",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         No",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prominent greater trochanter",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gluteus medius lurch (Trendelenburg gait)",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive Trendelenburg sign",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short leg limp, with toe-heel gait and out-toeing",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         No",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increasing adduction contracture of the hip, with compensatory genu valgum",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hip instability is a diagnostic finding.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The Klisic test is performed by placing the index finger on the anterior-superior iliac spine and the middle finger on the greater trochanter. An imaginary line between these points passes through or above the umbilicus in a child without developmental dysplasia of the hip (negative Klisic test). The line passes below the umbilicus if the hip is dislocated (positive Klisic test) because the greater trochanter is in a more superior position.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The hip. In: Tachdjain MO. Clinical Pediatric Orthopedics. The Art of Diagnosis and Principles of Management. Appleton &amp; Lange, Stamford, CT 1997. p.167.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11293=[""].join("\n");
var outline_f11_1_11293=null;
var title_f11_1_11294="Clin manif FRs NFRs";
var content_f11_1_11294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of fatal and near-fatal reactions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 388px; background-image: url(data:image/gif;base64,R0lGODlhPgKEAdUAAP////+ZMwAzmQAAAICAgH9MGQAZTMDAwIBmTYiIiEBNZr9yJj8mDEBAQLu7u0RERCIiIgAmcpmZmTMzM93d3REREWZmZu7u7j8zM8zMzFVVVaqqqnd3dwAMJtDQ0KCgoHBwcGBgYG9WPF85EwAJHAAcVm9cSXBzepCQkPDw8EBJXIB6cwADCTA8Vj8vKR8TBkBGU+Dg4CAgIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAA+AoQBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1dbX2Nna23QgCt/g4eLj5OXm5+jp6uvs7e7v8PHy8/T18CfcoQ0C/P3+/wADChxIsKDBgwgTKlzIsKHDhxAjSmyoIB+ofRMzatzIsaPHjyBDRqxo0RNGkShTqlzJsqXLgSRLcjr5sqbNmzhzvowpUxNN/51AgwodShQgz56YfhZdyrSpU448LQyYOsACgARTJ1xAukjp069gw4rtd1TIBQgSMgzIAGACB66KvI6dS7fuzbJXIVydICTBA7iJ5NodTLgwVCMUKmy4+jfvtgsD9HZ5kOCNYMOYM2s2WNZC4wR8GW8DXcHB5MpuLm9ezTrzUbWmAahl63YbhAQWrAJ4MGGq1dsALigmomFqBQoDTEtAS1WC1KkSdveuKqT4AK0Upr+VMEBI7gsPjCtR3bq8+bFHH2gggvX61mwOBlxwUGHrg7/xKSwHsH9IAggUCIGccnpRVoQFfN0HQH6gbTVBAhqsl0Fp3HlnQXzvjXfehhzShf8XV89Bt1tlyFEgnAMTRDdEbkMMyF+BqCVQwVQwAlBiiFWhJcQDElQIAIscDFABakiQ1+GRSN4FGBHCLbbXiDYOECBpRfwXoBADRPdAgW8htxgHNZbY4BARypZcftnpZuaVRxiZ5JtwovRhTxJU0OJaBpYY3ABEDhGekFdlpRd3Wf4JQZhSAmBdltlN9dZuQk5wIVVqthnnpZiyNOeSSdCX4R9uZirqqAttyukRtQkSKqmsthqQqafGZcCstNZq66245qrrrrz26uuvwAYr7LDEFmvsscgmSywMsVLSwALQRivttNRWa+212Gar7bbcdqstAc2GO0oDAZRr7rnopqv/7rrstuvuu/DGK++74IprLyDxcUHuvPz26++/AP9b770EZ7JvwAgnrPDC7Q5c8MNx1DlVAvk2OpUD8fVWQQbgiZfEwQyHLPLI8joM8clsPPDogt1pENqZye026adFkmzzzTiXazLKPJ+B4gAPZJCvjgDAbCEAQQ45Xs5MN52wwxJnaaN2PVfNhQaTKiqh0T+qqRabRoDs9Nhku+swB9HJqLWNEDhp9dtSGCp0dxlAEBnXucXn29Jl9+03ujsDsIGdE6yn6MpwJ47F11WI/ffjTu9MQdsL2i0k4opnDoXefFrhOOSg32zyhCoSobTmqKvxeeish+zwf2wV8UB9qdd+/8bqreeOsMOWQ4fcdbHbLrwYuOtufL+BD688GsUf7zy8yS8v/RjNP2/9utFPr70X1V/vvbnZby9+Ft1/733446dPRfnmW4+++vA/0YAICNRv//3456///vz37///AAygAP33gfgZ8AoNOMABF3iNBDLwgdNwIAQn6AwJUvCCybAgBjdIDA1y8IO/8CAIR6gLEZLwhLUwIQpXCAsVsvCFq3AhDGdoigaEgAA4zKEOd8jDHvrwh0AMohCHSMQiGvGISEyiEoVYQBrSYlWuiqI/YOVEVEBRilKkYhVriMUuIkSLWyTFFb3IKjCGURRjJOOozHjGi6jxjUYxQnxIRLU2fv8ijXC81GtmVJkyTc5tdtwEHvMIJ54kZjmVKVx1MBdIRggHbEUYJCGTFJPJVQY4DrBcBRjZSC8YKEpgyxfLohCzI0igMUWaJBxjQiiq9Ol0nQzDJ/U0BFFOpnSWUqUa8QIcP9EulrJEjZgoQ5XIVGw6Gvide+ITH+44QJlasdEvU6lLMvKSRFkJHjC/MEsp/cc0osyXBlB5pw3MEUuxidKXOEkESVZzQ2zcJjdRo5YL+EUI4ewO0WTzpyzZMjkZ6Gd0NrYEd77TPPGUZxfAFCAL6OWeLNuKOFGJoD1J4J8OqChkJLCB0GjooFhMqEK30DHgiSY4vYHAMaeiAfrc7aL/3UGnS+0mAQ30iZogjaJIRyoIyNAslzl11U55+giDBnUzQyVqI4x6VNcoFY0FiKpUp0rVqlr1qljNqla3KtUR3HCJYA2rWMcq1iY+tQ+27AL72neuBSjwrFaDqBPSqi+29sutcN0eXbewVrsGAK95hYvlIMCW64gok1QRjUsrEB3ESs2x3bGYVf6TleksJkS4DJtf5wXYwAIGAm/p3H8AsMlR3lNpdRJOdAZH2sqI0yqJyYCVkFMZzxChoh/brLw669mSXCBEVonZcvSUL7/QUkrFRG6AhlZMCUA0ZveUEY34ptt38VYIDyJTNnsbDe44KLgEam2gRKM0GanWdJXB/4qiKvVc0xh3AF+STM2qa9234nNiQhhcgCTFXWhYDALgfRF/aNSdey62sYMdsGGnRhUKtFc0hpJvm+hbXyN0szKf7G8+RkuHvtr1ulCqjssmAEkNW6M9pamDh9kK4k+Cpi8eNbEBV9y+FsfoOD+KsYzhR2Pz8ZZzkvnTBLS5Y/X1+HsgLvIGj+y9JCv5gky+npOfPMEoW2/KVH6glZ+H5SwvcMvO67KXZ8zVMpv5zGiu6gjsO2YKyrDNcI7Cm+NMZybMuc54bhOb88zngu65z4AO258DTWgA3LnQdD40ouGs6EWPudGOzjKkI/3kBqDgAJjOtKY3zelOe/rToA61qP9HTepSm/rUqC51CmRxALK6+tWwNuKgkdGACNj61rjOta53zete+/rXwA62sIdN7GIbe9glmLUqCNCAWDv72c5u9jOY2lSUREDZqcAhL7RdwWqD5dqy4LYuxM0MansbJOCOBblxsW5lmPvcHkk3LNptC3rTGt5OkbefYordm37C3rQAuDHeje+N6PtHU7lv50bRbhA04OEQh7gHViHwYhC84BnRNwcexO8Qi6LdDSjBrkmA7Sy0BwoZFhBjx/DiIlS8gxhfiryt5KMd+dsTII9AQDowaKwYrpdSgEw6iZByot/UAuyEAgX+5F7jqKjoL7+DLVkEhqKrNeZFkXfvEm7/c1LkfOc9r8DKgR4FtSDB6l2/00+lAIFo7im++ZUwAKJuh6lXKhAXxzpEDj5go3t9Z7UG+xH+Y17gtIewABhsYZejJsvlpjmtdE5zPM4fjxpWardNLi4H9ykIaMCehoOMNuleB7sXbTpamg5sVc8YrLAJs1DKEoDXYroNYNZFGPqY3ofCdx8BmeGA1zlAeD54CAjHoQmYEFs4YDghgLZozb/vgRJ0dOqzR02ilfsSpCsk905gS+lUKRFITwfTi9ZO6jFTBrAmTdmK/wgVNdAADPegyaXFTiviC4uojtPd64TvrPB1w9dzDzUxrRQZv0UpRTN0o3QVMxIZIcZ9NeIf/9gXXpnXXOzRGGBSTxHlfENHfnNgSxoQWuAkJZ8ke80lV/7xgDVSSsxnARtwG+shgQtyHImie/4HFABIccEneEbAYXaTfAQlBN7VFgFGBBUDX0jDJeq0hJQnAZZngU6gfEgzZEpYhKI3fu9jB5BRGaSzgE5oIBsgJeznH+TUhGASe7ExIXqhAUPiJU4oHdEHVDmIEzu4bD04gMVHhKJFKf91hLUUUxGmYKdEIxMoIPKBTgIGBe0xZIEiJCoSgy63hXYQNY9CFeLXT3TUYCq4I4aohkOgNGMYIIMoOKWEg3VohyV3CiBHAh3wirDYASywinGAdGUAdZTIB6dIeWrQif90mIo1cYfZtjMe8GmrxgeHxHI6Nne5uAe7iHZmkBiA1H/A+BLCiAogyIPTVo03cY2s2IzaWEEYMI7kWI7meI7omI7quI7s2I7u+I7wGI/yOI/w6AL0M0D8swKXkI14SAm7qGIUFpACGQAIsI/g2I+T8I8ZGDeooZBQAGYDGZFkU5CWwI/D6I8MuJBRAI1SAJES+ZE5Q5GVYJHYeJB70IiFhXpIQxVq4RuUsSW2lXhp40rNETN/8gBbcXmZFUkg2ZPeI5KUAHLJVUy0iHMmmQez8SN/cX5F4zYQxRsN1RhoARt+0pAO8B8XcAHZlX3U5ZNeqTtAOQkgtwDqwgBFOVf/HScEG7d2W/BHX0CSeNAfmQSGDGI3FmBPjfFJMYkW/ZF2yUF1uAGGfTlhX1mYrROWkOJ8GGgIY1mWPVdMN7VX0kcEiVFiU5BdCKeAnuIFcHkHSTlOYJiGoehcoeFiekEfaXGKKoNOWHkWlSFc2tdOhjmboBOWz1EEjMOYgEeW6WKWe4gEktmAK5J0T6A3N3UWKpIinHmUeYCSRUMjDiAcWXEBE1IVs2Q3E7By7bEWhOJMkAI0OSmFhEmb5Fk2QLlx6kV0dzcIjdmbBHgn0zlY0DQfaUk5eYGdn6JM02VhN8VhSDOHWdCZuOCR5Vmg7SKSNNdx+oUI7YkuvvmDxVRO/3TlJXR1g1ZyXhvZJ9I4BKe0nNNmoCAakkOwdfxGdoXQoOfyoFUiXwHVHKLUotBRoVcCUfsUJcUUmykXk0R4hgHKnLlAoCEapARpBDVnXomAouaiouwhXxrlT4nYpDBVBPZJozvJBBlGlUPAfB5aQULapQyDmD4iHDfHnrvpmL9Zgy+llcY0IzRFV7Z4UjXKBL+3G3OonF0goLcApF5aoIgZCUI5lFNxllRQmWSwmXfqowO6p4oKMH0KCXjKBWspBm65pc2gp4s6m436CI/6cYiap5f6qfKSqY6wqaFAqrNgqaDqlaLaCKb6b51qC6iaqj25qozQqkY5bd6Sq7q6q/+82qu++qvAGqzXYgIGuW2vmkKXlmrKuqzM2qzO+qzQGq2bNnEV2WzQdq3YukTSVkGCimitlq3gGq5E1K2+MGmUVmTmeq4ylq7qqmHs2q7c9a7w6lnyOq95Va/2elb4mq9Kta/8ylP++q8K1QDKUrAGe7AIm7AKu7C10gECmwZ5x41NYQAPyzwS+yYUW7FmELEXWxQZq7FkwLEdOxQfC7LEM7JHUrImCwYii7JAobK90xiJkZEr6wQt67I5AbO41B40W7N2hrMbArNZwSYO6bMFBbTnobJmoUiKaLQPibTmobR9gUpF67TUCLWaUbIOgJNaSSRVa7Vhg7WtUbIWg5P/j0gdYPuzYrsaUpu2jbO2bLtovpgacLsZbctTnLNwVTC3bXCzdasSdztS+eGAV8C3bOC3f4sSgatQg6ulfuF6N5mTKulYCfAf+PmdOJkByHR6IgJ7QTIV7ldZUzGNkZS4mLG48pS3d/lNeZGVW5leegFLF8pYrfkgLYcl6YV/3sEXStgXAEJbSjkeDDu8xFu8xnu8xOKwgTW4Z8EBEAWYATZcNwinzqEbuEEBxaGcMcMgLJgXVYGXimi4hiar5PsvYoa3ieKaENWawAGb4jW1zudcxuea/qEXMcNQSiiaQkC7jQFdPCqb5RvAu0WusZS3nydXkSuYp/mAlSuVWjIV/zi5ndGBiaYRYdLpHg8mvrEqwLR5vvb6tViwwRxsmB48ryCMQCOcwutSwm77kCr8wm3FZjHLYJjXwk0gwjAMkrxVo2UyhmxpwzyZwy+8w0NLWk5ywkCMw0IckSCmletRSjUMxLm1xCmcZKd1xD0rxUOgxFQckJ21ta7bR+vhw1rclV1cvp1VtlthMVVaxlt8xhzMwm48X3CMxgQ8xwBcx+Qrx3gcxHosq3zcx2/8x4B8x4LMxYTMYobcx4icyD62yHhsQ+I6yZRcyZYMVjEgyOsDyZpMQgHbyRj0yaDsZpw8yhwkyqasZaWcylC2yqxcZa78yqosy3aEyrTMY7F8y/8z1gL2cA+6jDqI+w9J9cucEsxTRMyZY8xkgcyKo8z8MMzMzBXOLADQHM09Mc1HMYYtopLWHCvYTHRctzZk3M3FbBNHYUvDAYbkvCTfjIT8BsVtvM6cAJlTwJFNSz7mXATojMXyPApSM85dgMQ2m8/uTCZjnIj9HApSozaKMp2ay1KcKzXyx3iKFyIOtl2yFx4l+MPt7IkiwsYJLQpUMQHe5yCVG2NMKX9z+Hwxk5S2NX9Hw3+/qCkhDQtZMiGXVUwWgL3XMcEluHSvaRoJuDfuWznqTB+0dLUrUc01XQn/vDFjsqKh2YLKkYj8pYSfuZTpxBsAWro1wdRNnZAqYiX/i+Jck0fBoPiHmXnRJnWKY5jFQtDRYc0LAi0F4hvXBD3XdA3XVbChR/vVem0vtXZshJ1rKhDY4tIAabbYjN3Yjv3YkB3Zkj3ZlF3Zln3ZmJ3ZjL1mp3BySFDXBeXIoj3aoBPIkyB0RyB/fC0/pN3aru00pi0JZqcEoG3Gr33buJ0wsR0Jjgd7qu0jLCJ7F2I58Ty+uX3cyO0vuw0Jbmp9yQHcwWU4K8daU5zc1n3d7LLcjyBKNPjbMRXcpqGf06tZ2F3e5v1Xe2YdZtsXtV0ISQh3qo0mVx0bK2dn533f1s1bWLkbj0Ioq60IojSIqg0pFTDf+JRg1Y3fCv7avAUm/1vxYoPz1iG04BTu2rxlMQXOTC5SrhXe4aLtZBGCI+3NCo3s4Sb+lVZ8ihveCyV+4i7+kddlNzW64rzQ4i9+416cy7Jg4zje45ul3Z7q40IewEAOq0N+5IX8oUi+5Ita5CnE5FDupU7+RPeIj1Z+5Vie5Vq+5Vze5V7+5WAe5mI+5mRe5iZArZWq44gNN7a85lXT5m7OM3Ae5ycz53T+MHZ+5wST53ou2Gre5xDD54DeLII+6KdS6IbOzl91yYze6I7+6JAe6ZKORGZ16KZ76QgVLtOM6ZwOEmC9jZ0e6obx6d0m6qZuF6Reqae+6nOR6uXG6rAOFjxhHY7oWMQpDf+bHuu6zhlDsKD8VRujuA25vuvE/ip3gmG1NWSZ9MO4XuzODhSzPmLLJSl6KwmYV3Obk5ZPMOJb/OzeriQwFu7D0ST+qCLYXpzavrHfvu4uERMy0lB8UVo4Xe58mHiV0SS8sTcW8xbyyXqW6x4PDdM2CcGSKyKoyO4ILxI8IWRs4VIDcOuKMJQCth/pNxtlMiEYE1PsF1uzS5pEkBy1+5qw+1EJX/If4eqEcO3dcSLKeYLL8XRRmngp6MA8rb0ZZb3RG5vdbvI8fxj+bO4xRSVQMooXDzNbUYbwK5P1u4DsG9SLqNQ9H/UUQQoqbxYLp4k0/BZqCiDT4U0OLMFgmMD/RQ31Ul/2X8QKhmrPdGv2bF8qrJAqvDgHw972l47y7kb3eM/rhM4AfN/3fv/3gB/4gj/4hF/4hn/4iJ/4ir/4jN/4jv/4kB/5kj/5lM/4L+BslW4MwXl2Y+rHUf75IlMAzbL5qd35eQz6qK8woh8rpM+fN5z6sJ8wq28NkctMNRw1FGNYBOWc2xlQyW6ZcR37wv8vs08NIX9ORLcyzCQzLh00qokb/3v6wz/971L80wC9e/UzQSNKuSGXaCFhs4Njtk395J8uxW/rWRr9wdD0m4813G8BWY2l/O1QwB/85X//6lL8wJ4oEAwEAOGQWDQekUnlktl0PqHCx2DwuDgG/8bpAJLBCi0WQII6yYypg8wjAbB0k43AnF633/F5/Z7f9/8BAwUHCQsNDxETFRcHC4gszBwgLoQSHqIwMzU3OTs9P+UYRUdJS01PUVNVVwMdhxwmLAbaKi8/b3FzdXc7Q1l/gYOFh4mLU12FKjYALpRreaGjpac9fY2vsbO1t7kRkQEqOAAynMdsqdHT1dGtu93f4ePlTb8dKqjEAdIGKNb9/wFuajePYEGDB+d9C7iQYcMoAxFGlDiR4imFDjFm1AixYkePH0HiuaiRZEl/HEOmVLkyoUmXL9OhZDmTZk1hI2Hm1MlJpk2fP4EqwrmTaFEmDQokVbqUaVOnT6FGlf86lWpVq1exZtW6lWtXr1/Bhs3KwGhZs0saHDi7lm1bt2/hxoWSVm5du3fx5tUbje5ev38BBxbstu9gw4cRJ1bMV+1ix48hR4ZcWHJly5cxt6WcmXNnz58BbgY9mnRp0w8bn1a9mrVp0a1hx5atuME+27dx59a9m3dv37+BBxc+nHhx48eRJ1e+nHlz58xlsH6NLgvAAw0CTqdW/R8BAtlT++Puzzv4gONdh1+HXt118wDZpysfWr26+Ojm/9M+7T7o/dL6m8Y9+s4LKL+T6ksnQGkOXOe/aBbs7EFoIoRmQP0SpM7A7wiEb8P3/qkwswl5EXGXCxEsEKAG1SFxFxP/dWExpgy3k45G/gJC0cEbAfywwxB9xFBF1VzUBcZcdGyRRwiDTNHDFTkU8knVQPAgu4A8ACGgKq8E6IMPtrQytIC+DLPL2dBMU8012WzTzTfhjFPOOems08478cxTzz357NPPPwENVNBBCS3U0EMR3WULMdKhoAIHhKBgAiokkCaDSQdg1B4uzoiGDCpoWRSdKSLFtNJoKNinjU8noESaBO6xRdRoJNgHAgAkpVSaXKughFVXoZFkgApOnZUXDs7ZFA5eT+UsgUkcXYaaTyEFQAMNANhgAGB3kUCcDNQApw0OJkBH2wuevSDaaWSp7tpst0WVnyHAPWOCfKCptdl0/9elRgMx3j03GnJxJbZeAO6VpoI2sEAX2nKMrGKIhQEgOOB4OdMgHzbsq7acAaqV5gI1wKXki2lv1VgKWqAhl4xkpAVZXiqwTaBcc6SZgGVrN9452Hk/DrlbCCRoJgObn4FmZFqUURkAjnmxRIiSAfgi6M6gfoBR6qqVWZ9mo3lAnJOx6GdmSLPeepdnKahVCK8HABsachKQeoxbIbxH4rSpSVifruXORVILKqjZlmdfpeKeDfiO2hay+YE78MqchpprmN8WepcLYpk63pOnAZeCyn3OBQLbwIlZc2jYQBrnaB4tWALSp5GgAlevhqZyDly3O3Q1aHfcc5OzyD0zfv8h3q7ai7nVxR6wKSY4bEi1PfphaaVx21psBYYmgW8fPdhv3cWIFnnsebkAApaZj0aDcjnnQHx8UZ3gkvO9Pyf6ctvHmgq1E/c/XJlKGu0SoLI65b00hEqA1NAes6QhrAHk41e7wtTGGuipSQwBgvWjghXQMIBWZY9mrjJWxKjQDwQOUFeJcuELYRhDGc6QhjW04Q1xmEMd7pCHPfThD4EYRCEOkYhFNOIRkZhEJS6RiU104hOhGEUpTpGKVbTiFbG4BA2oCnYYy+IX47TFZUwBfbm4R/PAmEY1ibFis7jAFrmwjEmJcQ1puIAETjcA7olwUq2C4wTVGMg1DkCOwCOiZKpuhSlCQqACnQJXuWQhAW1dYgptOKMgMTmbPxINHLbhXLgeOYRPpYED2sIWB2bRSTRmkpWlYeMQtgi2SXWKkY4UIRFM2UZLzquVvTTNK4XwxjRUAGHhGscWtoXHBeYSlavChy+hGU1pTpOa1bTmNbGZTW1uk5vd9OY3wRlOcY6TnOU05znRmU51rpOd7XTnO+EZT3nOk571tOc98ZnPKAQBADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11294=[""].join("\n");
var outline_f11_1_11294=null;
var title_f11_1_11295="Jabbing method";
var content_f11_1_11295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Techniques for transbronchial penetration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram shows the jabbing method used for tracheobronchial wall penetration in transbronchoscopic needle aspiration. The fiberoptic bronchoscope is held stationary while the needle assembly is jabbed forward.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research- Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_1_11295=[""].join("\n");
var outline_f11_1_11295=null;
